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SUMMARY 
 
 
In the last decades genetic factors are playing an increasingly important role in medical 
research, given the evidence for the existence of a heritable susceptibility for various 
diseases, including common cancers, based on reports of families with multiple affected 
relatives. Epidemiologists have utilized family history, usually of first-degree relatives, 
as a surrogate for genetic risk, aware that family history reflects the consequences of 
genetic susceptibilities, shared environment, and common behaviors.  
During my PhD I have dealt with two different aspects of family history, i.e., the role of 
family history of cancer in epidemiological cancer research (Chapter 1) and the use of 
complex family history score for assessing the level of disease risk in families (Chapter 
2).  
In particular, I have systematically examined the extent to which a family history of 
cancer might be a risk factor for cancer within the same cancer site and across multiple 
cancer sites, analyzing a large and comprehensive dataset based on a network of 
integrated case-control studies, conducted in Italy and Switzerland since the early 90's. 
The database included 1468 cases of cancer of the oral cavity and pharynx, 198 of the 
rhinopharynx, 505 of the esophagus, 230 of the stomach, 2390 of the colorectum, 185 of 
the liver, 326 of the pancreas, 852 of the larynx, 3034 of the breast, 367 of the 
endometrium, 1031 of the ovary, 1294 of the prostate, 767 of the renal cell, and a total 
of 16022 corresponding controls. Unconditional multiple logistic regression models, 
adjusted for the major possible confounding factors, and a procedure for controlling for 
multiplicity using a false discovery rate were used. The risk of developing cancer at a 
particular site was increased, although not always significantly, in subjects with a first-
degree relative affected by cancer at the same site, with odds ratios ranging from 1.4 for 
 iv 
 
pancreatic cancer, to 7.4 for ovarian cancer. Several across sites associations emerged, 
some of which possibly due to shared environmental exposures or lifestyle practices 
among family members (e.g., alcohol, smoking, unhealthy diet, infections) or to the 
inheritance of one or more predisposing gene mutations (high penetrance gene 
mutations, such as BRCA1/2 in breast and ovarian cancer, and/or low penetrance 
polymorphisms, as those involved in carcinogens metabolism, such as GST genes in 
oral cancer) or to a combination of both. The analysis I performed confirmed that 
several associations were stronger for a younger age at diagnosis in relatives. A detailed 
discussion of the findings is reported in paragraph 4 of Chapter 1. 
In addition to the investigation of the role of family history of cancer in cancer etiology, 
I have performed a statistical evaluation of the performance of different family history 
scores to recommend the measure that performs best. Family history scores summarize 
familial information and are used for estimating the familiar risk, i.e. the level of risk for 
a particular disease among members of that family. The simplest and most common 
family history scores are the dichotomous measure indicator, positive in families that 
have at least one relative with the disease, the number of affected family members, and 
the proportion of affected relatives, which takes into account the size of the family. The 
other family history scores proposed in the literature are statistics that describe the 
deviation of the observed situation from the expected risk for each family. More 
detailed information on family members (affected and unaffected) as well as incidence 
rates of the diseases of interest in strata of selected covariates are needed to compute 
these more complex family history scores. To evaluate family history scores’ 
performance I used two different complementary approaches: a data-derived approach, 
using data from the Italian HI-WATE study, with the aim of examining the power of 
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various family history scores in predicting a particular diseases (i.e., colorectal cancer), 
and a simulation approach to evaluate their accuracy of predicting the true familial risk. 
From 200 simulations for 48 different settings, Reed’s score and FHS2 seem to perform 
slightly better than the other scores. However, the simple proportion of affected 
relatives is not so far in terms of predictivity of the true familial risk. The use of this 
simple score seems therefore justified, at least until stronger evidence is brought for the 
advantages of using a more complex score. 
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Chapter 1 
Family history of cancer 
 
1.1 Introduction  
Overall, an estimated 12.7 million new cancer cases and 7.6 million cancer deaths 
occurred in 2008 worldwide [1]. By 2020, these figures are estimated to rise to over 16 
million new cases, with 10 million deaths. There may be more than 20 million new 
cases of cancer in 2030 [2]. 
The role of the environment on carcinogenesis has been actively investigated in many 
site-specific cancers, and a number of different types of exogenous factors are known 
causes of cancer. These include some aspects of food and nutrition, tobacco smoking, 
infectious agents, medication, radiation, and industrial chemicals, and also carcinogenic 
agents in food and drink [3].  
In the last decades genetic factors are playing an increasingly important role in cancer 
research, given the evidence for the existence of an heritable susceptibility for various 
common cancers [4], based on reports of families with multiple affected relatives.  
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Epidemiologists have utilized family history (FH), usually of first-degree relatives 
(FDR), as a surrogate for genetic risk, aware that FH reflects the consequences of 
genetic susceptibilities, shared environment, and common behaviors [4, 5].  
For many common cancers, including those of the digestive tract, and smoking- and 
alcohol-related cancers, the risk is significantly increased among subjects with a FDR 
affected by cancer at the same site [6-15]. However, the magnitude of the associations 
with FH have varied considerably between studies, with estimated relative risks (RR) 
ranging from about 2 to 5 for most cancers.  
A number of dominant susceptibility genes cause cancer at several sites. These include 
clustering of adenocarcinomas of the colorectum and endometrium in hereditary non-
polyposis colorectal cancer (HNPCC) families [16], the association of soft tissue 
sarcomas, leukaemia, brain and breast tumours in the Li–Fraumeni syndrome [17] and 
clustering in BRCA1 and BRCA2 families of cancers of the breast and ovary, with 
smaller risks for some other sites including colon, prostate and pancreas [18, 19]. It is 
then justified to ask whether there is a general susceptibility to cancer, causing 
clustering of discordant or different cancers in families. Some studies have addressed 
the question. A systematic study of familial correlations between 28 different types of 
cancer using the Utah population database revealed a number of significant associations 
[20]. Environmental and behavioral risk factors which are shared within families 
contribute to some associations, such as the familial clustering for cancers of smoking-
related sites. Clustering of cancers of the female genitalia, lip and oral cavity may 
reflect a common viral aetiology. Some associations are similar to those caused by rare 
penetrant genes. BRCA1 and BRCA2 presumably contribute to the associations 
between breast, colon and prostate and between ovary and pancreas, and the increased 
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risk of soft tissue cancers among relatives of breast cancer probands maybe due in part 
to the Li–Fraumeni syndrome. Truncating mutations in these genes are probably too 
rare to account for all of these associations, suggesting the existence of less penetrant 
variants, or perhaps other genes that affect some of the same pathways. Evidence of the 
HNPCC complex of cancers was seen in relatives of young uterine cancer probands. In 
addition to these expected associations between cancer sites, various significant 
associations such as thyroid cancer and non-Hodgkin’s lymphoma with breast cancer 
and leukaemias with colorectal cancer suggest previously unrecognized hereditary 
effects. A case-control study nested within a large cohort, the American Cancer Society 
Cancer Prevention Study-1 [21], found that the associations between FH and cancer 
mortality were generally stronger within cancer sites than across cancer sites. Within 
site associations were found for breast cancer, colorectal cancer, stomach cancer, and 
lung cancer. Across-site associations were observed for a FH of breast cancer as a risk 
factor for ovarian cancer mortality, stomach cancer as a risk factor for ovarian cancer 
mortality, and uterine cancer as a risk factor for pancreatic cancer mortality. In the 
Family-Cancer Database from the nationwide Swedish registries, familial aggregation 
between parents and offspring was observed for 5 concordant and 14 discordant cancer 
sites and 10 parental sites at which all cancer was increased in the offspring [22]. The 
concordant sites between the parent and offspring were colorectum, breast, melanoma, 
skin (squamous cell carcinoma), and thyroid. The aggregation at discordant sites in the 
parents and the offspring included stomach-breast, colorectum-sailvary glands, 
colorectum-breast, colorectum-lymphoma, colorectum-leukemia, liver-breast, pancreas-
breast, breast-melanoma, ovary-breast, prostate-breast, prostate-cervix, prostate-
multiple myeloma, kidney-melanoma, and nervous tissue-melanoma. More recently, a 
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study based on the Icelandic population database [23] analyzed familial aggregation of 
cancer cases both within and between pairs of cancer sites. It found 17 cancer sites 
involved in 20 significant pairs of sites. The estimated RRs for the 20 pairs are between 
1.1 and 1.7 for FDR relatives and between 1.1 and 1.5 for second-degree relatives. The 
highest RRs in FDR between cancer sites were seen for esophagus–cervix, with a RR of 
1.74, pancreas–ovary, with a RR of 1.66, and colon–rectum, with a RR of 1.64. Other 
cancer pairs that demonstrated significant familial co-clustering were: melanoma-
kidney, cervix-lung, stomach-brain, colon-stomach, prostate-colon, prostate-breast.   
Moreover, recent interest in the clustering of cancers across sites has stemmed from 
genome-wide association studies, which have identified more than 100 genetic variants 
spanning at least 20 cancers [24, 25]. 
The genetic contribution to diseases of complex origin, such as cancer, often is most 
salient to families of patients with early onset. Scanty information, however, is available 
on the variation of risk for FH in relation age at diagnosis of the affected relative. 
During my three-year PhD experience I have had the opportunity to handle a large 
amount of data from a series of well-conducted observational studies on cancer, 
systematically collecting information on cancer in FDR. This allowed me to explore the 
role of FH of cancer in cancer etiology. In particular, I have systematically examined 
the extent to which a FH of cancer might be a risk factor for cancer within the same 
cancer site and across multiple cancer sites, analyzing a large and comprehensive 
dataset based on a network of integrated case-control studies, conducted in Italy and 
Switzerland since the early 90's, and I have also investigated the possible modifying 
effect of age at diagnosis and sex of the affected relative [8, 26, 27]. Moreover, I 
focused on liver cancer and I quantitatively combined in a systematic meta-analysis all 
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published data on FH of liver cancer and liver cancer risk from observational studies 
[8]. 
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1.2 Methods 
1.2.1 The network of case-control studies 
Recruitment. Between 1991 and 2009, a series of hospital-based case-control studies on 
several neoplasms were carried out in various areas of northern (the greater Milan area; 
the provinces of Pordenone, Padua, Udine, Gorizia and Forlì; the urban area of Genoa), 
central (the provinces of Rome and Latina), and southern (the urban area of Naples) 
Italy, and in the Canton of Vaud, Switzerland. The studies included a total of 1468 cases 
of cancer of the oral cavity and pharynx (OP), 198 of the rhinopharynx (RP), 505 of the 
esophagus (i.e., squamous cell carcinoma of the esophagus, SCCE), 230 of the stomach, 
2390 of the colorectum (CR), 185 of the liver, 326 of the pancreas, 852 of the larynx, 
3034 of the breast, 367 of the endometrium, 1031 of the ovary, 1294 of the prostate, 767 
of the renal cell, and a total of 16022 corresponding controls (Table 1). 
All studies included incident cases, identified in the major teaching and general 
hospitals of the study areas. Controls were subjects admitted to the same network of 
hospitals as cases for a wide spectrum of acute, non-neoplastic conditions unrelated to 
known or potential risk factors for the corresponding cancer site. Overall, 8.5% of 
controls were admitted for traumatic conditions, 24.2% for non-traumatic orthopedic 
conditions, 29.4% for acute surgical conditions, and 37.9% for miscellaneous other 
illnesses.  
The proportion of refusals of subjects approached was less than 5% in Italian centers, 
and about 15% in Switzerland. The study protocol was revised and approved by local 
ethics committees of the hospitals involved according to the regulations at the time of 
each study conduction, and all participants gave informed consent. 
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Data collection. Subjects were face-to-face interviewed using similar structured 
questionnaires, administered by trained interviewers. The questionnaire included 
information on socio-demographic characteristics, anthropometric measures, lifestyle 
habits (e.g., tobacco smoking, alcohol drinking), dietary habits, a personal medical 
history, and, for women, menstrual and reproductive factors, and use of oral 
contraceptives (OC) and hormone replacement therapy (HRT). Subjects were 
specifically asked for how many sisters and brothers they had, and whether their 
parents, siblings, children, grandparents or spouse had ever had any cancer (excluding 
nonmelanoma skin cancer). For each relative with a history of cancer, the subject was 
asked to report the vital status at the time of interview, current age or the age at death, 
cancer site and age at diagnosis. The history of cancer in first-degree only, i.e., parents, 
siblings and sons/daughters, was considered in the analysis. On account of recall and 
classification difficulties, some sites were combined (i.e., all CRC, all Hodgkin and 
non-Hodgkin lymphoma, myeloma and leukemia, as well as cervix and corpus uteri).  
In some of the studies in the network of case-control studies a blood sample was 
collected from each subject.  
 
Statistical analysis. Odds ratios (OR) of 13 different cancers according to FH of 
selected cancers in FDR and the corresponding 95% confidence intervals (CI) were 
estimated by unconditional multiple logistic regression models [28]. The models 
included terms for quinquennia of age, sex (when appropriate), study centre (when 
appropriate), year of interview, education, alcohol drinking, tobacco smoking, body 
mass index (BMI), number of brothers and sisters. For female cancers, models included 
further terms for parity, menopausal status, age at menopause, and OC and HRT use, 
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and, for breast cancer only, age at first birth. Additional models were used to assess the 
potential modifying effect of sex and age at diagnosis of the affected FDR. In further 
analyses, I accounted for the problem of multiple comparisons using a false discovery 
rate controlling procedure, according to the Benjamini-Hochberg method [29]. 
Additional stratified analyses, as well as analyses of interaction between FH and 
selected lifestyle exposure were also performed for liver and laryngeal cancer.  
All statistical analyses were performed with SAS 9.1 statistical software (SAS Institute, 
Cary, NC). 
 
1.2.2 Meta-analysis: a focus on liver cancer 
I performed a Medline search in PubMed up to April 2011 using the string “(liver OR 
hepatocellular) AND (cancer OR neoplasm OR tumor OR carcinoma) AND (“family 
history”)”, limiting the search to the publications written in English language and 
following the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
guidelines [30]. The PubMed search identified 232 articles. From these, I selected 14 
reports giving information on the association between FH of liver cancer and liver 
cancer risk. Studies considering FH of any cancer or FH of liver diseases were not 
considered. Some reports were excluded as based on data later updated [31-33], or 
because reporting data from case-control studies nested in previously identified cohorts 
[34, 35]. Three additional papers were identified through the review of the reference 
lists of the publications retrieved [36-38]. Finally, besides our present case-control 
study, the meta-analysis included other 8 case-control [36-43] and 4 cohort studies [44-
47].  
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Whenever available, I considered multivariate risk estimates, adjusted for the largest 
number of potential confounding factors; otherwise I computed the crude OR (and the 
corresponding 95% CI) from the distribution of cases and controls according to FH of 
liver cancer. In a study reporting the adjusted OR but not the corresponding 95% CI 
[38], I used the standard error of the crude OR. I pooled the RR estimates of liver cancer 
for FH of liver cancer from each study using random-effects models, which consider 
both within- and between-study variation [48]. Heterogeneity among studies was 
assessed using the χ2 test (results were defined as heterogeneous for a p-value<0.10) 
[49].  
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1.3 Results 
1.3.1 Results from the network of case-control studies 
Table 2 gives the distribution of cases of cancer at 13 different sites and the 
corresponding controls according to a positive FH of selected cancers. The 
corresponding ORs and 95% CIs are reported in Table 3 (in bold, significant ORs at the 
0.05 level after accounting for the problem of multiple comparisons). In general, the risk 
of developing cancer at a particular site was increased, although not always 
significantly, in subjects with a FDR affected by cancer at the same site, with ORs 
ranging from 1.4 for pancreatic cancer, to 7.4 for ovarian cancer.  
With regard to the across sites associations, without controlling for the problem of 
multiple comparisons, significant associations or associations of borderline significance 
emerged between cancer at OP and FH of laryngeal (OR=3.3, significant [s]), skin 
(OR=3.3, not significant [ns]), or breast cancer (OR=1.5, ns); cancer at RP and FH of 
colorectal (OR=3.1, s) or skin (OR=4.6, ns) cancer; SCCE and FH of OP (OR=4.1, s) or 
stomach (OR=1.8, ns) cancer; cancer at CR and FH of stomach (OR=1.2, ns), liver 
(OR=1.4, ns), skin (OR=2.2, ns), ovarian (OR=2.1, ns), prostate (OR=1.6, ns) cancer, or 
of all hemolymphopoietic (HLP, OR=1.4, ns) cancers; cancer at the pancreas and FH of 
stomach (OR=2.4, s) or bone (OR=2.7, ns) cancer; cancer at the larynx and FH of 
colorectal (OR=1.5, ns), or skin (OR=8.4, s) cancer. 
For female cancers, the risk of breast cancer was increased among those with FH of 
stomach (OR=1.2, ns), colorectal (OR=1.5, s), skin (OR=3.0, s), uterine (OR=1.4, ns), 
prostate (OR=1.6, s), or of all HLP (OR=1.7, s) cancers; the risk of endometrial cancer 
among those with FH of oral and pharyngeal cancer (OR=2.4, ns), stomach (OR=1.8, 
 11 
 
ns), kidney (OR=4.2, ns), or brain (OR=4.2, s) cancer; the risk of ovarian cancer among 
those with FH of colorectal (OR=1.6, s), laryngeal (OR=1.8, ns), breast (OR=2.3, s), or 
of all HLP cancers (OR=1.6, ns). 
Prostate cancer risk was elevated in subjects with at least one FRD affected by 
colorectal (OR=1.5, ns), lung (OR=1.5, s), ovarian (OR=7.4, s), bladder (OR=3.4, s), or 
kidney (OR=3.4, s) cancer; the risk of renal cell cancer among those with a FDR with 
laryngeal (OR=2.2, ns), uterine (OR=1.7, ns), ovarian (OR=4.1, ns), or prostate 
(OR=1.7, ns) cancer.  
Individuals with a FH of any type of cancer are generally at a higher risk of developing 
all the cancers considered. When FH of the cancer under investigation was not 
considered, the magnitude of these associations decreased. 
Significance at the 0.05 level after Benjamini-Hochberg correction was found for the 
following associations: cancer at OP and FH the corresponding cancer (corrected-
pvalue=0.004) and laryngeal cancer (corrected-pvalue=0.010); SCCE and FH of oral 
and pharyngeal cancer (corrected-pvalue=0.034); cancer at stomach and FH of the 
corresponding cancer (corrected-pvalue=0.012); cancer at CR and FH of cancer at the 
same site (corrected-pvalue<0.001); cancer at liver and FH of liver cancer (corrected-
pvalue=0.062, borderline); cancer at the larynx and FH of the corresponding cancer 
(corrected-pvalue= 0.028); cancer at the breast and FH of the corresponding cancer 
(corrected-pvalue<0.001), colorectal (corrected-pvalue=0.049), skin (corrected-
pvalue=0.062), or all HLP cancers (corrected-pvalue=0.036); cancer at the ovary with 
FH of cancer at the same site (corrected-pvalue<0.001) or at breast (corrected-
pvalue<0.001); cancer at prostate and FH of prostatic (corrected-pvalue<0.001) or 
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bladder (corrected-pvalue=0.034) cancer; cancer at the renal cell and FH of kidney 
cancer (corrected-pvalue=0.028). 
 
Sex and age at diagnosis of the affected relative 
Table 4 presents results for FH according to sex and age at cancer diagnosis of the 
affected FDR. For each cancer site investigated in this report, we showed RR estimates 
only for FH of cancer at 1) the same site, 2) sites for which a significant increased risk 
emerged in the previous analysis, 3) any sites, and 4) any sites excluding the one under 
investigation.  
Some of the associations resulted restricted to (or stronger for) having a male rather than 
a female affected FDR. This is the case of the associations between oral and pharyngeal 
cancer and FH of cancer at the same site (OR for a male affected=3.1 [s] - OR for a 
female affected=0.8), rhinopharyngeal cancer and FH of colorectal cancer (OR=4.0 [s], 
vs. 0.5), colorectal cancer and FH of colorectal cancer (OR=3.5 [s] vs. 2.2 [s]), liver 
cancer and FH of cancer at the same site (OR=3.6 [s] vs 1.1 [ns]), pancreatic cancer and 
FH of stomach cancer (OR=3.5 [s] vs 1.4 [ns]), and breast cancer and FH of skin cancer 
(OR=10.7 [s] vs 1.0). The associations between prostate cancer and FH of bladder 
cancer (OR for a female affected=11.3 [s], for a male affected=2.5 [borderline]) and 
between renal cell cancer and FH of kidney cancer (OR=6.2 [s] vs 2.9 [ns]) were 
stronger for having a female rather than a male affected relative. 
Concerning age at cancer diagnosis in FDR, several associations were stronger for 
earlier diagnosed FDR. This is particularly evident for SCCE and FH of cancer at OP, 
stomach cancer and laryngeal cancer and FH of cancer at the same sites, and breast 
cancer and FH of cancer at the skin. Opposite findings emerged for a few associations.  
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Additional analyses 
Laryngeal cancer. Table 5 gives the ORs for FH of laryngeal cancer in strata of age, 
tobacco and alcohol consumption. The ORs were somewhat higher in younger 
probands, current smokers and in heavy drinkers, although the tests of heterogeneity 
were not significant. The combined effect of tobacco, alcohol and FH of laryngeal 
cancer is shown in Figure 1. As compared to the lowest risk category, i.e., non-smokers, 
drinkers of less than 28 drinks per week, without FH, the risk was increased in those 
with one or more factors in the highest risk category: the OR was 1.4 (95% CI, 0.3–6.2) 
for nonsmokers and moderate drinkers with FH of laryngeal cancer, 18.2 (95% CI, 
13.7–24.2) for current smokers and heavy drinkers without FH and 37.1 (95% CI, 9.9–
139.4) for smokers and heavy drinkers who also reported a FDR with laryngeal cancer. 
 
Liver cancer. After further adjustment for hepatitis B virus (HCV) and/or hepatitis C 
virus chronic infection, the OR of primary liver cancer for FH of liver cancer was 2.38 
(95% CI, 1.01-5.58) (data not shown). Figure 2 shows the interaction between FH of 
liver cancer, and HBV surface antigen (HBsAg) and/or antibodies against HCV (anti-
HCV) positivity. Compared to the lowest risk category (i.e. subjects without FH and 
with no chronic B/C hepatitis), the ORs were 2.94 (95% CI, 0.94-9.21) for subjects not 
chronically infected by hepatitis viruses and with FH, 38.19 (95% CI, 21.97-66.39) for 
those with chronic infection with hepatitis viruses and no FH, and 72.48 (95% CI, 
21.92-239.73) for those exposed to both risk factors. No significant interaction emerged 
between these two factors (p=0.61).  
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1.3.2 Results from the meta-analysis 
Besides the case-control study on liver cancer of our research group, from the literature 
search I identified 8 other case–control and 4 cohort studies, for a total of 3627 liver 
cancer cases. The main study characteristics are reported in Table 6. Most studies were 
conducted in South-eastern Asia, where the prevalence of HCV/HBV infection is high; 
only 3 studies, besides the present one, were carried out in Western countries. Figure 3 
shows the forest plot for the association between FH of liver cancer and HCC risk. The 
pooled RRs for liver cancer were 2.80 (95% CI, 2.19-3.58) for case-control, 2.28 (95% 
CI, 1.58-3.29) for cohort, and 2.50 (95% CI, 2.06-3.03) for all studies, with no 
heterogeneity between study type (p=0.17). When studies not allowing for hepatitis 
were excluded from the analyses, the overall RR was 2.28 (95% CI, 1.85-2.18) (RR 
estimate based on studies either including a term for hepatitis in the logistic regression 
model or performed on subjects with hepatitis infection only). Analyses by sex showed 
a pooled RR of 2.80 (95% CI, 2.14-3.66, p for heterogeneity=0.21) for males from 9 
studies (including the present one) [36-39, 41, 44-46], and of 1.55 (95% CI, 0.92-2.64, p 
for heterogeneity=0.77) for females from 6 studies (including the present one). When 
only the 6 studies (including the present one) reporting risk estimates for both males and 
females separately were considered, the pooled RR for males became 2.39 (95% CI, 
2.03-2.81) while the one for females remained the same. 
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1.4 Discussion 
During my PhD, I have provided a comprehensive picture on the role of FH of cancer at 
different sites on the risk of several cancers, using original data from a network of 
Italian and Switzerland case-control studies, with the same inclusion criteria and 
questionnaire. The associations between FH of cancer at a particular site and the risk of 
developing the same disease were substantially confirmed. An original aspect of this 
study is the systematic investigation of all cancer sites in FDR, and consequently the 
possibility of obtaining quantitative estimates of risks of 13 selected cancers with 
reference to familial aggregation of cancer at other sites. For most of the cancers 
investigated in this report, a somewhat increased risk according to FH of cancer at other 
sites emerged. Some of these associations may be explained by shared environmental 
factors among members of the same family, some of others by inherited genetic 
susceptibilities, some of others by a combination of both. Concerning the possible 
modifying effect of age at diagnosis, this analysis confirmed that several associations 
were stronger for a younger age at diagnosis in relatives.  
In the following, a brief discussion of the major findings for each cancer site 
investigated. 
 
Oral and pharyngeal cancer. Our findings of an elevated risk of oral and pharyngeal 
cancer in subjects with FH of oral and pharyngeal or laryngeal cancers are in broad 
agreement with other reports [20, 50, 51]. An inherited component of susceptibility to 
oral and pharyngeal cancer has been suggested by case reports of families with multiple 
affected members [52-54], by epidemiologic studies indicating familial tendency to oral 
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and pharyngeal cancer or other cancers of upper aerodigestive tract [55-62], by 
segregation analysis in FDR [63], by elevated risks associated with genes involved in 
DNA repair maintenance of genetic stability (e.g., P53) [64, 65], and by elevated risks 
associated with polymorphic genes involved in the metabolism of tobacco, alcohol and 
other carcinogens (e.g, ADH, NAT2, GSTM1, GSTT1, CYP) [66-70], also in 
consideration that carcinogen-matabolizing enzimes are expressed in the oral cavity, 
suggesting that matabolism of carcinogens could occur at this site.  
Familial aggregation of oral and pharyngeal cancers may also be due to shared 
environmental exposure to the main risk factors, i.e., alcohol and tobacco. This is 
supported by the stronger association for having an affected male than female DFR, 
since smoking and alcohol drinking are more common among the former, and by the 
observed elevated risk associated with FH of laryngeal cancer. However, the risk of oral 
and pharyngeal cancer was only moderately increased in individuals with a FH of 
esophageal cancer and not related to a FH of cancer at other sites related to alcohol or 
tobacco (i.e., liver or lung) [71, 72], suggesting that tobacco and alcohol cannot totally 
explain this association. The association with FH of skin cancer has not to my 
knowledge been previously reported in the literature, and needs therefore independent 
confirmation. Although the point estimate of the OR was around 3.3, this estimate was 
based on 8 cases and 7 controls only; moreover, significance was lost after controlling 
for multiple comparisons.  
 
Rhinopharyngeal cancer. A modest, not significant, 20% increased risk of 
rhinopharyngeal cancer emerged for subjects with FH oral and pharyngeal cancer. A FH 
of rhinopharyngeal cancer have been reported to significantly increase the risk of 
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developing the disease in other epidemiological studies on the issue, with ORs ranging 
from 4 to 20 for individuals with an affected FDR as compared with those with no 
affected relatives [73-85]. On the contrary Abdulamir et al. [86] found that a positive 
FH of head and neck cancer do not increase rhinopharyngeal cancer risk. Almost all 
these studies, however, were conducted in high-risk populations, including those from 
southern China and south-eastern Asia, which may be substantially different from this 
Southern European population in terms of tumor histology, and lifestyle behaviors. 
Moreover, I have considered in the analysis FH of oral and pharyngeal cancers 
combined, which included rhinopharyngeal cancer, since no study subjects reported a 
FDR affected by that specific tumor. Inherited cancer syndromes are not presumed to 
account for a high proportion of cases. Rather, common genetic variation, particularly 
involved in genes that play a role in the immune response to Epstein-Barr virus 
infection (i.e., HLA) or the metabolism of environmental carcinogens, including 
tobacco (e.g., CYP, GSTM, GSTT) are likely to be an important factor in 
rhinopharyngeal cancer development [87]. 
The positive association emerged with FH of colorectal cancer should be interpreted 
with caution, in the absence of confirmatory findings from other studies [83, 85]. 
Moreover, the corresponding OR lost its significance after multiple comparisons 
controlling. 
 
SCCE. An elevated but not significant risk of SCCE emerged for subjects reporting at 
least one FDR affected by esophageal cancer. Several epidemiological studies from 
high-risk esophageal cancer areas in China and the Caspian Littoral of Iran found that 
esophageal/gastric cancer aggregates in families, and that a FH of esophageal/gastric 
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cancer is a risk factor for the disease [88-95]. Results have been less consistent in 
studies from other areas of the world. No association between FH of esophageal cancer 
and risk of SCCE was found in three case-control studies from the U.S. [96, 97] and 
Sweden [98], including about 200 cases each. Conversely, a case-control study from 
Japan on 167 cases with squamous cell carcinoma of the hypopharynx or cervical 
esophagus found an OR of 5.1 (95% CI: 0.7-36.1) in subjects with a FH of esophageal 
cancer, and an OR of 2.6 (95% CI, 1.1-6.3) for a FH of cancers of the esophagus, head 
and neck or lung [99]. The Swedish Family-Cancer Database, which includes 10.1 
million individuals and about 6,000 cases with esophageal cancers, found a standardized 
incidence ratio of 4.9 (95% CI, 1.8-9.6) for having a parent with SCCE and of 12.6 
(95% CI, 1.2-36.2) for having a SCCE in a sibling [100]. 
This data showed that a FH of oral/pharyngeal and stomach cancer increases the risk of 
esophageal cancer. It is possible that some misclassification between contiguous parts 
of the digestive tract has occurred in reporting cancer in the relatives. In Western 
countries, however, cancers of the oral cavity/pharynx and esophagus show remarkable 
similarities in etiology and geographic distribution [101]. Moreover, synchronous and 
metachronous cancers in both the esophagus and the OP have been observed [100, 102, 
103]. Familial aggregation of SCCE and oral/pharyngeal cancers may be due to shared 
environmental exposure to the main risk factors, mainly alcohol and tobacco. However, 
the risk of SCCE was not increased in individuals with a FH of cancer at other sites 
related to smoking (lung), alcohol (liver) or both factors (larynx). A joint inherited 
susceptibility to both cancers, thus, cannot be ruled out. Similarly, in high-risk areas of 
China, cancers of the esophagus and the gastric cardia are both very frequent, and a link 
between the two is conceivable [95]. 
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Stomach cancer. Our study confirms that a FH of stomach cancer in FDR increases the 
risk of stomach cancer, particularly when the relative was diagnosed in earlier age. No 
differences emerged according to the sex of such relative. The results are in line with 
most epidemiologic studies investigating the issue, which reported a risk of gastric 
cancer between 1.5 and 3.5 for subjects with relatives with stomach cancer [4, 20, 23, 
97, 98, 104-121]. Both the long term decline in gastric cancer in developing countries 
and the results of migrant studies suggest that environmental factors predominate in the 
etiology of gastric cancer. Nonetheless, the observed association may therefore reflect a 
shared environment, but genetic factors might also contribute to this familial clustering. 
Helicobacter pylori (HP) infection, one of the most important risk factor for stomach 
cancer, tends to aggregate among family members [122-124]; thus, the excess risk 
associated with FH may be at least partly due to concordance in HP infection status. 
However some studies found that FH of gastric cancer and HP infection were 
independent risk factors [125, 126], although in one study this was found only for 
women [126]. Similarity in lifestyle (e.g., smoking) and diet (e.g, processed/salted food) 
could also partially explain the familial aggregation of stomach cancer. On the other 
hand, the role of genetic susceptibility has been strengthened by the fact that discovery 
mutations in the E-cadherin gene have recently been associated with an increased risk of 
familial or sporadic gastric cancer [127] and by the observation that genetic 
polymorphisms of Interleukin-1 (IL-1) promote development of the intestinal type of 
gastric cancer associated with HP infection [128, 129]. Among the studies that 
investigated the association with FH of other cancers, a cohort study from Utah found 
an association between a FH of brain/central nervous system, female genital cancer and 
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stomach cancer [20].  A cohort study from Iceland found an increased risk of stomach 
cancer for a FH of cervix, endometrium, ovary, colon, esophagus, thyroid and brain 
cancer [23]. In a case-control study from Sweden the risk of cancer of the cardia was 
increased among persons who reported having a FDR with breast cancer [98]. In the 
‘‘Swedish Family Cancer Database’’ sites associated with stomach cancer were 
endometrium and urinary bladder in siblings, and male genital cancers other than 
prostate in fathers [106]. Some studies reported no significant association between a FH 
of any cancer other than stomach cancer [97, 113]. In our study no increase in risk was 
found for a FH of cancer at all sites excluding stomach. The number of exposed subjects 
were however small and the estimates were subject to substantial random variation for 
any specific cancer site.  
 
Colorectal cancer. These analyses showed that FH of colorectal cancer increased the 
risk of developing colorectal cancer of about three-fold. The significance of the 
association persisted even after multiple testing correction. No appreciable difference in 
risk emerged in this study with the age at diagnosis in relatives. Elevated, but not 
significant, risk of colorectal cancer emerged for FH of stomach, liver, ovarian, prostate, 
all HL, and skin cancers. However, for these across sites associations, significance at 
0.05 level was lost after Benjamini-Hochberg correction.  
Many epidemiological studies estimated the risk of colorectal cancer in individuals with 
a FH of the disease, with RR estimates ranging from 1.21- to 9.33-fold [10, 130] as 
compared to individual without FH. Colorectal cancer clustering in families may be 
explained by common unhealthy behaviors among members of the same family, 
including a diet rich red and processed meat, smoking and alcohol, inherited genetic 
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susceptibility and/or their interaction. The two major familial syndromes that underline 
inherited susceptibility are the familial adenomatous polyposis and HNPCC, also called 
Lynch syndrome. Familial adenomatous polyposis is a rare autosomal dominant 
syndrome, caused by mutations in the APC gene (the prevalence of mutations is about 1 
in 10,000 individuals), and characterized by the development of multiple colorectal 
adenomas. One or more of the polyps will almost progress to cancer. HNPCC is an 
autosomal dominant syndrome, caused in most cases by germinline mutations in two 
genes in DNA mismatch repair, MSH2 and MLH1. HNPCC is most strongly associated 
with colon cancer but also to other malignancy, involving the endometrium, urinary 
tract, stomach, and biliary system. In summary, no more than 10% of colorectal cancers 
are due to inherited mutations in these single genes. A higher but very uncertain 
proportion may partially caused by inheritance of variants in metabolic or other genes 
that alter the way in which lifestyle factors influence the risk. These include selected 
polymorphisms of genes involved in the metabolism of aromatic and heterocyclic 
aromatic amines (present in cigarette smoke and red meat cooked by high-temperature 
cooking techniques), such as NAT2, NAT1, and CYP1A2 [131], folate, such as 
MTHFR, and nonsteroidal anti-inflammatory drugs (i.e., NSAIDs), such as the UGTs 
gene. Other genes that have been implicated in the aetilogy or progression of colorectal 
cancer include other DNA repair genes [132-135], hormone receptors [135], and insulin, 
insulin-like growth factors. 
The elevated colorectal cancer risk found for FH of ovarian and prostate cancer suggests 
an involvement of the BRCA1 gene, which has been linked to colon cancer [19, 136]. 
Moreover, ovarian cancer risk is increased among HNPCC families. Also liver cancer 
has been moderately associated to BRCA1 mutation [136]; this, together with similar 
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alcohol and smoking behaviors among family members could at least in part explained 
the association between colorectal cancer and FH of liver cancer. However, against the 
hypothesis of un involvement of the BRCA1 gene, no association emerged with FH of 
breast cancer. 
FH of gastric cancer has been found to increase colorectal cancer in another study [137]. 
This association may be explained by shared unhealthy behaviors among family 
members, including smoking and alcohol, as well as by HNPCC, which increases the 
risk of developing both colorectal and stomach cancer. However, the absence of 
association with FH of other cancer sites associated to HNPCC, e.g., endometrium and 
urinary tract, do not support such explanation. Moreover, a recent meta-analysis 
suggested a small elevation in colorectal cancer risk for HP infection, a strong risk 
factor for stomach cancer.  
Beside colorectal cancer, polymorphisms within the MTHFR gene have been recently 
related to hematopoietic cancers in some [138, 139] but not all studies [140, 141]. This 
possible relation may partially explain the observed association of colorectal cancer risk 
with FH of HLP cancers. However, this association is yet to be confirmed by other 
studies. 
 
 
Liver cancer. A significant threefold increased HCC risk was found for subjects with a 
FH of liver cancer, with stronger association for a male affected relative and a younger 
age at relative diagnosis; further adjustment for serological markers of hepatitis B 
and/or C viruses (HBV, HCV) infection did not substantially change these results (OR= 
2.38, 95% CI, 1.01-5.58, data not shown). The RR estimate in this database is consistent 
with the overall evidence from published data. The pooled OR from the meta-analysis I 
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performed was RR of 2.50 (95% CI, 2.06-3.03) from 13 studies [8]. HBV and HCV 
transmission among family members, together with other shared environmental risk 
factors (e.g. alcohol drinking), may be responsible for part of the observed familial 
aggregation of liver cancer. Familial clustering of HCC has been frequently reported in 
eastern Asia [44, 142], where HBV infection is common [143]. However, FH was found 
to be related to HCC risk even after adjustment for other risk factors, and in subjects 
without hepatitis B and C serum markers [39, 40, 45]. Several inherited disorders, 
including 1-antitrypsin deficiency, hemocromatosis, and porphrya cutanea tarda, have 
been associated to HCC [144]. Specific genes studies have yielded conflicting results. 
Directly opposite effects have been reported for the association of several enzymes, 
including cytocrome P450 2E1 (involved the metabolism of smoking and alcohol), the 
glutathioneS-transferases and the epoxide hydrolases (involved in the process of 
aflatoxine B1 detoxification in hepatocytes). No apparent associations were observed 
with polymorphisms in the gene encoding alcohol-metabolizing enzymes [144].   
 
Pancreatic cancer. The current analysis showed a 40% not significant increased risk of 
pancreatic cancer among subjects with FH of the same cancer, and an OR of pancreatic 
cancer of 2.4 (95% CI, 1.2-4.7) for those with FH of stomach cancer. This association 
emerged for a male affected FDR. Epidemiological literature showed nearly a two-fold 
increased risk for developing pancreatic cancer in subjects with FH of cancer at the 
pancreas [145, 146]. To my knowledge, among the few available studies analyzing 
across sites associations [21, 41, 88, 100, 147, 148], only one cohort of about 1.1 
subjects in the Cancer Prevention Study-II supported a role of FH of stomach cancer in 
pancreatic cancer aetiology, with RRs of 1.22 (95% CI, 1.09-1.36) for one and 1.53 
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(95% CI, 1.02-2.30) for two or more affected relatives [148]. Although chance could 
not be excluded as a possible explanation of the association observed, also in 
consideration that significance was lost after Benjamini-Hochberg p-value correction, 
HP infections within families may also play a role [149, 150]. HP infection is an 
established risk factor for stomach cancer [151], being responsible for two-thirds of all 
gastric cancers [152]; moreover, a recent meta-analysis of six studies involving a total 
of 2,335 patients found a significant association between HP seropositivity and the 
development of pancreatic cancer [153]. However, the fact that the association between 
FH of stomach cancer and pancreatic cancer is limited to having a male affected relative 
weights against a major role of HP infection in familial clustering. Also tobacco 
smoking, which is positively related to both pancreatic and stomach cancer, may also 
explain part of the observed association. However, the absence of any relation between 
stomach cancer and FH of pancreatic cancer does not support such explanations. 
 
Laryngeal cancer. These analyses confirm that a FH of laryngeal cancer in FDR 
increases the risk of laryngeal cancer, and provides further evidence that the risk is 
higher when the affected relative is younger than 60 years. Moreover, further analyses 
on this database (data not showed) found that the risk is independent from that of 
tobacco smoking and alcohol drinking. A FH of skin, colorectal or kidney cancer are 
associated to a somewhat increased laryngeal cancer risk. However, these across sites 
associations are not longer found after correction for multiple comparisons. A few 
epidemiologic studies have investigated the risk of laryngeal cancer in subjects who 
have a FH of cancer. A study based on a Utah population database found a standardized 
incidence ratio of laryngeal cancer of 8.0 (95% CI, 2.1-17.9) in 246 subjects with FH of 
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laryngeal cancer [20]. A case-control study conducted in China on 288 laryngeal cancer 
cases found an OR of 2.3 (95% CI, 1.2-4.5) in subjects with a FH of that malignancy 
[154]. The International Head and Neck Cancer Epidemiology Consortium (INHANCE) 
pooled data from case-control studies, including a total of 2,357 laryngeal cancer cases, 
showed an OR of 2.1 (95% CI, 1.6-2.7) in subjects reporting a FDR with head and neck 
cancer [155]. A study from Poland on 2839 FDR of 760 laryngeal cancer patients, found 
that the incidence rates of laryngeal, lung, stomach, and breast cancers (only early-onset 
breast cancer) were significantly increased in families with laryngeal cancer, while that 
of colon cancer was significantly decreased, as compared to the general population 
[156]. Several genetic polymorphisms in genes involved in the metabolism of 
carcinogens, DNA repair or in several other processes have been associated to laryngeal 
cancer risk, although results were not always consistent [157, 158]. Given that the 
differential ability to metabolize carcinogens matters only when exposure occurs, it is 
also possible that the familial risk reflects both a higher genetic susceptibility to 
laryngeal cancer together with an aggregation of exposures. However, no increased risk 
was found for FH of oral cavity and esophageal cancer, i.e, other cancers also caused by 
alcohol and tobacco. For lung cancer, too, no significant excess emerged. The 
associations with FH of skin, kidney and colorectal cancer are not confirmed in other 
studies and should therefore be interpreted with caution. 
 
Breast cancer. These results confirm that breast cancer risk is increased in women with 
a FH of breast cancer. The risk is somewhat higher when the affected FDR was 
diagnosed before the age of 60. Elevated risk of breast cancer emerged for FH of 
colorectal, skin, prostate, and all HLP cancers combined. After adjustment for multiple 
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testing, in addition to that with FH of the corresponding cancer, the association with FH 
of colorectal cancer persisted.  
The overall OR of 2.4 associated with FH of breast cancer is comparable with most 
estimates in other populations [6, 7]. In particular, a collaborative re-analysis combining 
individual data from 52 epidemiological studies found ORs of 1.80 (95% CI, 1.70-1.91), 
2.93 (95% CI, 2.37-3.63), and 3.90 (95% CI, 2.03-7.49) for one, two, and three or more 
affected FDR, respectively, as compared to no affected relative. Moreover, the risk 
ratios were greater the younger the relative was diagnosed [7].  
It has been estimated that 5–10% of all breast cancers can be attributed to highly 
penetrant germinline mutations [159]. A further proportion is caused by a number of 
moderate penetrance genes. At present, around 20 low penetrance genes have been 
identified cumulatively; when all have been discovered, these may contribute a higher 
proportion of familial breast cancer [160]. These genes appear to interact, although this 
has yet to be completely elucidated. The most important identified with high-risk genes, 
conferring 40–85% lifetime risk, included BRCA1, BRCA2 and P53. BRCA1 and 
BRCA2 are human genes that belong to a class of genes known as tumor suppressors. In 
normal cells, BRCA1 and BRCA2 help ensure the stability of the cell’s genetic material 
(DNA) and help prevent uncontrolled cell growth. Whilst pathogenic mutations in 
BRCA1/2 have high penetrance, they occur relatively rarely: 1 in 500-1000 individuals 
carry a pathogenic mutation in BRCA1, and 1 in 600-800 in BRCA2. Pathogenic 
mutations in BRCA1/BRCA2 are known to increase the risk of breast cancer by 10- to 
20-fold, and to confer an increased lifetime risk of ovarian cancer of 40-60% for 
BRCA1 and up to 30% for BRCA2. Mutations in the tumor suppressor gene P53 (Li-
Fraumeni syndrome) also give a high risk of breast cancer (i.e., an 18- to 60-fold 
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increased risk as compared to the general population), although the frequency of 
germline mutations is even lower (<1%). Moderate risk genes (20–40% risk) included 
PALB2 (which encodes for a protein that was identified as a binding partner of 
BRCA1), BRIP1 (which encodes for a protein that interacts with BRCA2), ATM (gene 
of ataxia telangiectasia) and CHEK2 (tumor suppressor gene, with a mutation 
prevalence of about 0.2-1%). A number of common polymorphisms have now been 
identified to be associated with a slightly increased or decreased risk of breast cancer; 
most of these are involved in the metabolism of carcinogen.  
Some but not all studies reported an increased risk of breast cancer in women with a FH 
of ovarian cancer. In this study the estimated OR was 1.7 (not significant). The excess 
of ovarian cancer in relatives of women with breast cancer has been related to BRCA1 
mutations, which have been shown to account for the majority, if not all, of hereditary 
breast-ovarian cancer families [161]. An increase in the risk of breast cancer of about 
50% in women with a FH of colorectal cancer was observed in this and other studies. 
Cancers of the breast and CRC share some etiological factors, including positive social 
class correlates, a diet poor in fruit and vegetables, and alcohol drinking and a low level 
of physical activity [162]. Moreover, an increased risk of colon cancer has been 
observed in carriers of BRCA1 mutations [18]. The same study showed an increased risk 
of prostate cancer, as well. An elevated risk of prostate cancer in relatives of breast 
cancer patients has been reported in a few but not all studies. In this study a significant 
60% increase in breast cancer risk was observed for FH of prostate cancer. We found a 
significant association between breast cancer and FH of all HLP cancers, with an OR of 
1.5 (95% CI, 1.0-2.7) for FH of leukemia (data not shown). Breast cancer and leukemia 
have been linked within families that have rare germ-line mutations in either the P53 
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gene (Li-Fraumeni Syndrome) or ataxia telangiectasia gene (ATM) [17, 163, 164]. 
However, these mutations are rare and thus responsible for few cancer cases. 
We found a significant increased breast cancer risk for FH of skin cancer. 
Epidemiological studies have provided suggestive evidence of a link between 
melanoma and breast cancer. Moreover, registry-based and hospital-based studies have 
shown an increased risk of breast cancer among female melanoma survivors and vice 
versa [165-169]. Breast cancer and cutaneous melanoma occur at a higher frequency 
than expected by chance in the same individual. In addition, a high risk of breast cancer 
in relatives of cutaneous melanoma patients from families with strong aggregations of 
cancer has been suggested [170]. The commonly reported environmental risk factors for 
breast cancer and cutaneous melanoma are dissimilar and could not explain the 
observed clustering; otherwise, a genetic relationship between cutaneous melanoma and 
breast cancer has been suggested by reports of a higher risk of cutaneous melanoma 
among BRCA2 mutation carriers and an elevated frequency of breast cancer in 
CDKN2A 113insArg mutation families [19, 171]. Furthermore, in Polish population, a 
common missense variant of the CDKN2A gene (A148T) appeared as a low-penetrance 
breast cancer susceptibility gene [172]. 
 
Endometrial cancer. The present analysis found that a FH of uterine cancer in FDR is 
associated with an increased risk of endometrial cancer, and the risk seemed to be 
higher for FDR younger than 60 years at diagnosis. A FH of cancer at other sites, 
including brain, CRC, stomach, and OP, was also associated with a somewhat increased 
risk of endometrial cancer. After multiple testing corrections, none of these associations 
however were statistically significant at 0.05 level. Only a few studies have evaluated 
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the risk of endometrial cancer associated with history of cancer in FDR [173-179]. Most 
studies [173, 174, 176, 177, 179] found an association with FH of endometrial cancer, 
but in one study [175] there was no association. Results from this database are therefore 
compatible with the overall epidemiologic evidence. Cancer of the cervix and corpus 
uteri differ considerably in terms of aetiology [180, 181]. However, many women were 
not able to distinguish between cancer of the cervix and of the corpus uteri in relative. 
When subgroup analyses were performed, the OR of endometrial cancer was 2.97 (95% 
CI, 0.74-11.16) for FH of endometrial cancer, and 0.84 (95% CI, 0.04-16.53) for FH of 
cervical cancer. Specific genetic bases of endometrial cancer have been studied. 
HNPCC is most strongly associated with colon and endometrial cancer [16]. The 
lifetime risk of endometrial cancer among women with HNPCC is 50%–60%. However, 
overall, HNPCC accounts for only 2% of all endometrial cancers. Other potential 
genetic etiologies have been investigated using DNA analysis to examine potential 
mutations with likely physiologic relationships to development of endometrial 
malignancies. Genes with mutations that are associated with endometrial cancer with 
unknown magnitude and clinical significance include the sex hormone binding globulin 
gene; Fas gene promoter; P53 gene; mitochondrial gene polymorphisms; the 
methylenetetrahydrofolate reductase gene; the methylguanine DNA methyltransferase 
gene; the androgen receptor gene; CYP19 and CYP17 gene mutations; ATM, CHEK2, 
ERBB2 haplotypes; the MDM2 gene mutation and the catechol-O-methyltransferase 
gene [179]. Two studies [174, 177] found an association between FH of cancer of the 
CRC (OR=1.9) or the colon (standardized incidence ratio=3.3) and endometrial cancer 
risk. With regard to clusters of intestinal cancer, in this database one case (aged 45 
years) reported four relatives with intestinal cancer, that is, the mother, two brothers and 
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one sister. One case and one control (both aged 66 years) reported two FDR with 
intestinal cancer. However, the case also reported a grandfather with intestinal cancer 
and three relatives with a history of cancer at other sites, whereas the control reported a 
grandmother with breast cancer. As mentioned before, HNPCC is characterized by an 
increased risk of colon cancer and other malignancies, including cancers of the 
endometrium, ovary, stomach, small intestine, and brain. This may at least partially 
explain some observed elevated risk of endometrial cancer associated to FH of these 
cancers [16]. The association with brain cancer, moreover, may be also in part attributed 
to misclassification of metastasis. Although endometrial and breast cancers share some 
reproductive, hormonal and genetic risk factors, in this and other studies [173-175, 177, 
178], a FH of breast cancer was not associated with endometrial cancer risk. 
 
Ovarian cancer. This study confirms that a FH of ovarian cancer in FDR increases the 
risk of ovarian cancer. A FH of a few other cancer sites, including breast, CRC, larynx 
and all HLP, was also positively associated with ovarian cancer risk, and the OR was 
increased for FH of any cancer. After controlling for multiple comparisons, however, 
the only significant associations (with 0.05 level) were those between ovarian cancer 
and FH of cancer at ovary and breast.  
The finding of an elevated risk of ovarian cancer in subjects with a FH of cancer at the 
same site are in broad agreement with other reports [20, 21, 177, 182-192], although the 
point estimate obtained in this analysis is somewhat higher than in other studies (i.e., 
7.4). Given the broad confidence interval due to the small number of subjects reporting 
a FH of ovarian cancer, results from this analysis none the less do not contrast with the 
pooled OR of 3.1 (95% CI 2.6–3.7) estimated from a meta-analysis of published studies 
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[15], which became 4.0 when only case–control studies were considered. A similar 
association with FH of ovarian cancer emerged according the age of the onset of ovarian 
cancer in the affected FDR, consistently with other reports [15]. 
The OR of 2.3 in women with a history of breast cancer in FDR is slightly higher than 
in most studies, ranging between 1.3 and 1.8 [21, 182-185, 187, 189, 190, 193]. The 
associations between ovarian malignancies and FH of the cancer at the same as well as 
of breast cancer may be attributable to BRCA1/2 mutations and to a shared response of 
ovary and breast to pregnancy hormones [194, 195]. The familial aggregation of ovarian  
The 4-fold increase in prostate malignancy with colorectal and oral and pharyngeal 
cancer may be attributed in some degree to HNPCC-related genes, since HNPCC shows 
colonic malignancies with these cancers, as well as to shared environmental factors, 
including smoking habits (for both associations) and diet/obesity (for the association 
with colorectal cancer).  
 
Prostate cancer. In our study, a FH of prostate cancer in FDR was directly associated 
with prostate cancer, with no meaningful differences according to age of the affected 
relatives. The risk of prostate cancer was also increased in subjects with a FH of cancers 
of the ovary, bladder, kidney, lung, and, to a lesser extent, CRC and breast. However, 
after adjustment for multiple testing, most of the associations across sites lost their 
significance.  
cancer risk in subjects with a FH of the disease is somewhat higher than the risk of 2–3 
estimated by some systematic meta-analyses [14, 196-198]. Both common 
environmental risk factors and genetic influences can contribute to the familial 
clustering of prostate carcinoma. Genome-wide linkage searches have implicated 
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several regions in inherited prostate cancer, e.g. HPC1, PCaP, HPCX, CAPB, HPC20, 
HPC2/ECAC2 [196, 197], but confirmatory studies at these loci have produced 
discordant results. Other susceptibility genes with an associated increased risk for 
prostate cancer include BRCA1, with carriers having a 3.3-fold increased risk of 
prostate cancer compared to the general population [18] and BRCA2 associated with a 
2–5% increased risk of disease [199]. With regard to shared environmental factors 
among family member, obesity, which runs into family, a diet rich in unsaturated fats, 
and cigarette smoking may be in part responsible to the prostatic cancer clustering. The 
epidemiologic studies investigating the association of FH of other cancers and risk of 
prostate cancer have yielded contrasting results: significant associations with a FH of 
cancers of the ovary [200, 201], stomach [202, 203], CRC [20, 201, 204], skin [205], 
breast [200-202, 206-208], kidney [200, 202, 209], central nervous system [20, 210], 
Hodgkin's and non-Hodgkin’s lymphomas [20, 201], and liver [201] have been 
reported. Other studies found no significant association with FH of any cancer other 
than prostate cancer [211-213]. An association of prostate cancer risk with FH of 
ovarian cancer was found in this database. Although the point estimate of the OR was 
around 7, this was based on 10 cases and 3 controls only, with a lower confidence limit 
of 1.4. Most of the ovarian cancers reported appeared to be rapidly lethal. This rules 
against minor ovarian conditions (e.g., ovarian cysts) being misreported as cancer. A 
relation between these 2 cancers is not implausible. Male carriers of germline mutations 
of the genes BRCA1 and BRCA2, 2 genes predisposing to breast and ovarian cancer, 
have been found to be at high risk of prostate cancer. Compared to noncarriers, men 
carrying a mutation of BRCA1 had a relative risk of prostate cancer of 3.3 [18] and men 
carrying a mutation of BRCA2 of 4.7, which became 7.3 below age 65 years [19]. The 
 33 
 
50% not significant elevate prostate cancer risk emerged for FH of breast cancer may be 
explained by the same mutations of the genes BRCA1 and BRCA2. A further suggestion 
that in a few prostate cancer cases breast/ovarian cancer predisposition genes may play 
a role is given by the clusters of these cancers found in relatives: 1 prostate cancer case 
(aged 61 years) reported ovarian cancer in 3 sisters, and 3 prostate cancer cases (aged 
70, 72 and 73 years) reported 3 cases of breast cancer each in female FDR. I also found 
an association with FH of cancers of the bladder and the kidney; for the former the 
association was higher for female relatives, and could thus not be explained by 
misreporting of prostate cancers. It is possible that cases had urinary symptoms before 
diagnosis and were thus more sensitized to urinary tract cancers in the family than 
controls. However, a high risk of kidney cancer in FDR of prostate cancer cases has 
been previously reported. In a cohort of Swedish families with hereditary prostate 
cancer, the risk of kidney cancer was 2.5 (95% CI, 1.2– 4.8) overall and 4.6 (95% CI, 
1.8 –9.5) for women [202]. In a record linkage study from Iceland, the risk of kidney 
cancer in FDR of prostate cancer cases was 1.7 (95% CI, 0.7–3.8) for males and 2.5 
(95% CI, 1.1–5.7) for females [209]. The association between the risk of prostate cancer 
and FH of lung cancer has not been reported by others in my knowledge. A possible 
explanation of the observed elevated risk associated to FH of cancer at CRC may be the 
sharing of a diet rich in red meat among family members, as it was related to both 
intestinal and prostate cancer. 
 
Renal cell cancer. These analyses confirm that a FH of kidney cancer in FDR increases 
the risk of renal cell cancer. An elevated, not significant, risk of renal cell cancer 
emerged for FH of uterine and ovarian cancer.  
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FH of renal cell cancer was positively associated to the risk of the corresponding cancer 
even after multiple comparisons correction. Findings of an elevated risk of renal cell 
cancer in subjects with a FH of kidney cancer are in broad agreement with other reports, 
although our point estimate is somewhat higher than in other studies [20, 214-220]. 
Given the broad confidence interval due to the small number of subjects reporting a FH 
of kidney cancer, our results are nonetheless in line with other reports. A multicenter 
case-control study in Central Europe, including 1,097 cases of kidney cancer and 1,555 
controls, found an OR of kidney cancer of 1.40 (0.71-2.76) for FH of kidney cancer 
[220]. A population-based case-control study from Canada [214], based on 518 RCCs 
and using a mailed questionnaire, did not find an association between FH and risk of 
RCC (OR= 1.1 in both sexes). Conversely, three other population-based case-control 
studies [215-217] reported significantly increased risks: a stud from Denmark on 368 
RCCs found an OR of 4.1 in men and 4.8 in women [215]; an international study 
conducted in Denmark, Sweden, Germany, Australia, and the United States and 
including 1,732 RCCs found an OR of 1.6 for one FDR affected, whereas 7 cases and 
no controls reported two affected relatives [216]; and a study from Los Angeles, United 
States, based on 550 RCCs, found an OR of 2.5 for an affected FDR [217]. Three 
linkage studies analyzed the familial risk of kidney cancer. In a systematic population-
based assessment using the Utah Population database [20], based on 687 kidney 
cancers, the familial RR was 2.5. In the nationwide Swedish Family Cancer database 
[218], including 23,137 kidney cancers, the standardized incidence ratio of kidney 
cancer was 1.6 in offspring and 4.7 in siblings of kidney cancer cases. Finally, a 
population-based familial aggregation analysis based on 1,078 renal cell cancer cases in 
Iceland [219] found relative risks of 2.5 for siblings and 2.2 for parents. Several 
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autosomal dominant inherited syndromes predisposing to renal cell cancer have been 
described, the most common being the von Hippel-Lindau syndrome, characterized by 
excesses of renal cell cancer and other neoplasms, including those of the central nervous 
system, eye, inner ear, endocrine glands, and pancreas, and caused by germ-line 
mutations in the von Hippel-Lindau tumor suppressor gene (i.e., VHL gene) [221, 222]. 
However, these syndromes are rare and probably, as for many other cancers, most of the 
familial risk in older patients is not due to these highly penetrant genes [4]. Other 
susceptibility genes may exist, with lower penetrance but much higher frequency in the 
population, which might account for more cases of renal cell cancer. Identification of 
these genes is extremely difficult because their low penetrance does not cause striking 
familial aggregations [4]. A common lifestyle characterized by smoking and 
overweight/obesity may shared by members of the same family may also explained 
some of the familial clustering observed. As concerning the association of FH of other 
cancers with renal cell cancer, in the Utah Population database [20], no significant 
associations were found between FH of other cancers and risk of kidney cancer, 
whereas in the Swedish Family Cancer database [218], discordant sites that were 
associated with kidney cancer in siblings were ovaries, endocrine glands. In our study 
too, cases reported a FH of ovarian cancer more frequently than controls, although the 
association was not significant, probably given the small numbers.  
 
Strengths and limits. These case–control studies have a few limitations that should be 
considered in interpreting these findings. Selection bias should be limited as in the 
control group were included subjects admitted for a wide spectrum of acute, non-
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neoplastic conditions, unrelated to the major risk factors for cancer. Moreover, the 
almost complete participation has likely reduced selection bias. 
Data on FH of cancer was self-reported, and it is possible that cancer patients may be 
more interested in understanding their family cancer history in greater detail, especially 
if multiple family members have been affected by a specific cancer [223]. However, an 
analysis in this population showed a good reliability of data on FH of all cancers 
provided by hospital controls, with a kappa statistic of 0.70 for all cancers, 0.70 for liver 
cancer, and 0.80 for any digestive tract cancers [224]. In a recent systematic review 
from The Agency for Healthcare Research and Quality (AHRQ), self-reported FH about 
common cancers appeared to be fairly accurate. Specificity across all cancers types 
ranged from 91 to 99%, while the sensitivity values showed greater variability, with 
breast cancer having the highest values (around 85-90%) [225]. In the Connecticut 
Family Health Study, reports from FDRs were more accurate than those from second 
degree relatives; we therefore considered FDRs only in our analysis [226]. 
With reference to confounding, RR estimates we adjusted for the main recognized risk 
factors, including tobacco smoking, alcohol drinking, overweight/obesity, and, for 
female cancers, reproductive factors.  
A possible limitation in these studies is the lack of information on important risk factors 
for cancer among family members, including alcohol drinking (in particular for 
laryngeal, oral, and esophageal cancer), smoking habits (in particular for oral, laryngeal 
cancer, pancreatic cancer), some inherited diseases, diet (in particular for colorectal and 
stomach cancer), body weight, HP and HBV/HCV infection (for stomach and liver 
cancer, respectively), which may partly explain the observed familial aggregation across 
sites.   
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In the present study 13 cancer sites and 17 exposure variables were covered and some 
associations were likely to appear by chance. We presented also significant results after 
multiple comparisons adjustment. However, without adjustment, only one OR was 
significantly decreased, compared with 25 significantly increased ones (Table 3), 
suggesting that chance findings could be limited. 
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1.5 Tables and Figures of Chapter 1 
 
 
Table 1. Number of cases of selected cancer sites and controls in the network of case-
control studies, and corresponding median age. Italy and Switzerland, 1991-2009. 
Cancer site  
Cases 
(M/F) 
Median 
age 
(yrs) 
Controls 
(M/F) 
Median 
age (yrs) 
Total 
(cases/controls) 
OP  1190/278 58 2553/1208 58 1468/3761 
Rhinopharynx  157/471 52 41/123 52 198/594 
SCCE  438/67 60 919/340 60 505/1529 
Stomach  143/87 63 286/261 63 230/547 
Colorectum  1401/989 62 2586/2357 58 2390/4943 
Liver  149/36 66 278/126 65 185/404 
Pancreas  174/152 63 348/304 63 326/652 
Larynx  770/82 62 1564/406 61 852/1970 
Breast  -/3034 55 -/3392 56 3034/3392 
Endometrium  -/367 60 -/798 61 367/798 
Ovary  -/1031 56 -/2411 57 1031/2411 
Prostate  1294/- 66 1451/- 63 1294/1451 
Renal cell cancer  494/273 62 988/546 62 767/1534 
Abbreviations: M, males; F, females; OP, oral cavity and pharynx; SCCE, squamous 
cell carcinoma of the esophagus; yrs, years. 
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Table 2. Distribution of cases of cancer at 13 different sites and corresponding controls according to a positive family history of selected cancers. Italy and 
Switzerland, 1991-2009. 
 Cancer site (cases:controls) 
 OP RP SCCE Stomach CR Liver Pancreas Larynx Breast Endometrium Ovary Prostate Renal cell 
FH              
OP
a 
53:47 3:6 21:12 4:14 35:63 1:16 10:16 21:43 32:37 10:11 17:32 25:36 21:33 
Esophagus 16:32 1:5 12:14 3:4 17:32 2:2 4:4 6:15 21:20 2:10 6:17 4:15 6:15 
Stomach  63:113 4:16 29:39 30:31 132:224 13:23 21:20 48:82 148:138 22:32 62:109 63:75 49:74 
CR 47:116 12:17 22:47 10:31 221:166 6:28 19:33 49:80 150:112 28:38 60:89 84:58 39:63 
Liver 39:86 6:19 15:28 13:20 91:141 22:18 20:25 34:63 107:107 15:32 44:88 51:50 32:60 
Pancreas 18:61 6:6 6:17 2:14 37:62 4:6 10:15 15:37 38.49 6.23 21:37 26:22 11:32 
Larynx 33:25 1:3 4:14 0:3 30:49 0:5 9:15 29:27 43:50 1:12 24:42 18:20 9:14 
Lung  89:170 11:38 32:66 22:42 143:270 17:39 29:58 64:111 205:194 29:54 81:168 111:88 58:94 
Bone 3:16 1:2 3:4 2:3 13:24 3:2 6:7 4:15 20:33 4:7 1:22 12:5 0:6 
Skin 8:7 3:3 1:3 1:2 12:11 1:3 0:1 7:3 26:10 2:2 6:9 8:3 7:6 
Breast 65:111 3:21 15:42 8:22 107:206 10:25 22:32 31:81 311:145 21:36 104:111 82:64 41:65 
Uterus
b 
20:53 3:11 9:20 5:10 60:96 4:16 8:21 8:21 108:84 19:25 31:52 40:35 26:32 
Ovary 2:10 1:3 1:3 0:2 15:17 1:1 1:2 3:5 19:13 3:4 27:9 10:2 5:3 
Prostate 12:34 7:7 7:19 3:10 39:55 5:7 8:13 12:27 59:42 13:16 17:35 90:28 19:21 
Bladder 11:24 1:0 0:4 1:7 26:47 4:3 2:6 5:15 42:37 5:7 10:29 31:10 6:15 
Kidney 1:20 3:5 1:3 0:5 19:29 2:3 3:4 11:7 32:25 6:5 8:12 16:6 18:8 
Brain 13:37 5:9 8:14 2:4 41:66 3:6 9:9 9:24 41:42 10:7 13:36 26:28 17:21 
All HLP cancers
c 
26:65 6:15 6:21 4:13 52:82 2:10 10:16 10:16 92:57 9:16 32:54 32:32 27:31 
All sites 441:922 69:181 161:342 96:199 919:1450 84:166 162:250 162:250 1256:1039 164:287 468:829 596:515 321:514 
excluding  cancer 
index
 
388:875 66:175
d 
149:328 66:168 698:1284 62:148 152:235 152:235 945:894 145:262
e 
441:820 788:964 303:506 
Abbreviations: OP, oral cavity and pharynx; RP, rhinopharynx, CR, colorectum; HLP, hemolymphopoietic; SCCE, squamous cell carcinoma of the esophagus. 
a 
Including rhinopharyngeal cancer. 
b 
Including cancer of the cervix, endometrium and uterus not otherwise specified. 
c
 Including Hodgkin lymphoma, Non 
Hodgkin lymphoma or unspecified, leukemia and mieloma. 
d
 Family history of all cancer sites, excluding cancer of the oral cavity and pharynx. 
e
 Family 
history of all cancer sites excluding cancer of the uterus. 
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Table 3. Odds ratios
a
 and 95% confidence intervals of cancer at 13 different sites according to family history of selected cancers. In bold, significant associations at 
level 0.05 after adjustment for multiple testing according to the Benjamini-Hochberg method. Italy and Switzerland, 1991-2009. 
 Cancer site in the proband 
 OP RP SCCE Stomach CR Liver Pancreas Larynx Breast
b 
Edometrium
 b
 Ovary
 b
 Prostate Renal cell 
             
FH             
             
OP
c 2.6 
(1.6-4.2) 
1.2 
(0.3-5.7) 
4.1 
(1.7-9.8) 
0.6 
(0.2-1.9) 
1.2 
(0.8-1.8) 
0.2 
(0.0-1.2) 
1.2 
(0.5-2.9) 
0.8 
(0.5-1.5) 
0.9 
(0.6-1.5) 
2.4 
(0.9-6.1) 
1.0 
(0.5-1.8) 
0.6 
(0.4-1.1) 
1.4 
(0.8-2.4) 
               
Esophagus 
1.5 
(0.7-3.2) 
0.7 
(0.1-6.2) 
1.7 
(0.6-4.5) 
1.7 
(0.4-7.9) 
1.0 
(0.6-1.9) 
3.7 
(0.4-32.0) 
1.7 
(0.4-7.5) 
0.9 
(0.3-2.5) 
1.1 
(0.6-2.0) 
0.4 
(0.1-2.0) 
0.8 
(0.3-2.2) 
0.3 
(0.1-1.0) 
0.9 
(0.3-2.5) 
              
Stomach  
1.4 
(0.9-2.0) 
0.5 
(0.2-1.5) 
1.8 
(1.0-3.3) 
2.7 
(1.6-4.6) 
1.2 
(1.0-1.6) 
1.8 
(0.8-4.1) 
2.4 
(1.2-4.7) 
1.2 
(0.8-1.9) 
1.2 
(1.0-1.6) 
1.8 
(1.0-3.4) 
1.2 
(0.8-1.7) 
0.9 
(0.6-1.3) 
1.3 
(0.9-2.0) 
              
Colorectum 
1.0 
(0.6-1.4) 
3.1 
(1.4-7.0) 
1.1 
(0.6-2.1) 
0.8 
(0.4-1.6) 
2.8 
(2.3-3.5) 
0.5 
(0.2-1.3) 
0.9 
(0.5-1.7) 
1.5 
(1.0-2.3) 
1.5 
(1.1-1.9) 
1.6 
(0.9-2.9) 
1.6 
(1.1-2.4) 
1.5 
(1.0-2.2) 
1.3 
(0.8-2.0) 
              
Liver 
1.1 
(0.7-1.8) 
0.8 
(0.3-2.4) 
0.9 
(0.4-1.9) 
1.8 
(0.8-3.7) 
1.4 
(1.0-1.8) 
3.0 
(1.4-6.5) 
1.5 
(0.7-3.0) 
1.3 
(0.8-2.1) 
1.2 
(0.9-1.6) 
1.2 
(0.6-2.4) 
1.3 
(0.9-2.0) 
1.2 
(0.8-1.8) 
1.1 
(0.6-1.7) 
              
Pancreas 
0.9 
(0.5-0.6) 
1.8 
(0.5-6.4) 
0.8 
(0.3-2.4) 
0.3 
(0.1-1.5) 
1.4 
(0.9-2.1) 
2.3 
(0.5-10.1) 
1.4 
(0.5-3.3) 
1.3 
(0.7-2.6) 
0.8 
(0.5-1.2) 
0.7 
(0.3-1.9) 
1.6 
(0.9-2.8) 
1.3 
(0.7-2.5) 
0.7 
(0.3-1.4) 
              
Larynx 
3.3 
(1.7-6.3) 
1.0 
(0.1-14.5) 
0.8 
(0.2-2.9) 
NE 
1.3 
(0.8-2.1) 
NE 
1.1 
(0.4-2.8) 
2.8 
(1.5-5.1) 
1.0 
(0.6-1.5) 
0.4 
(0.0-2.9) 
1.8 
(1.0-3.2) 
1.1 
(0.6-2.3) 
2.2 
(0.9-5.3) 
              
Lung  
1.2 
(0.9-1.7) 
0.8 
(0.4-1.7) 
0.9 
(0.6-1.6) 
1.3 
(0.7-2.3) 
1.1 
(0.9-1.4) 
0.9 
(0.5-1.8) 
0.9 
(0.5-1.5) 
1.4 
(0.9-2.0) 
1.2 
(0.9-1.4) 
1.1 
(0.7-1.8) 
1.1 
(0.8-1.5) 
1.5 
(1.1-2.0) 
1.2 
(0.9-1.8) 
              
Bone 
0.7 
(0.2-2.6) 
1.4 
(0.1-16.2) 
2.9 
(0.5-16.0) 
2.0 
(0.3-12.8) 
1.4 
(0.7-2.8) 
4.8 
(0.6-36.8) 
2.7 
(0.8-9.0) 
0.5 
(0.1-1.7) 
0.7 
(0.4-1.2) 
0.6 
(0.1-2.3) 
0.2 
(0.0-1.4) 
1.5 
(0.5-4.7) 
NE 
              
Skin 
3.3 
(1.0-10.7) 
4.6 
(0.9-24.1) 
1.1 
(0.1-11.9) 
1.5 
(0.1-17.2) 
2.2 
(0.9-5.2) 
0.4 
(0.0-7.0) 
NE 
8.4 
(1.7-41.8) 
3.0 
(1.4-6.4) 
3.1 
(0.4-22.9) 
1.3 
(0.4-4.2) 
2.2 
(0.5-9.1) 
2.3 
(0.7-7.2) 
              
Breast 
1.5 
(1.0-2.2) 
0.4 
(0.1-1.3) 
1.1 
(0.5-2.2) 
0.9 
(0.4-2.2) 
1.1 
(0.8-1.4) 
1.2 
(0.5-2.8) 
1.4 
(0.7-2.6) 
0.8 
(0.5-1.2) 
2.6 
(2.1-3.2) 
1.3 
(0.7-2.4) 
2.3 
(1.7-3.2) 
1.5 
(0.9-2.0) 
1.3 
(0.8-2.0) 
              
Uterus
d 0.9 
(0.5-1.7) 
0.6 
(0.1-2.4) 
1.0 
(0.4-2.6) 
1.4 
(0.5-4.3) 
1.3 
(0.9-1.9) 
0.5 
(0.1-1.7) 
1.0 
(0.4-2.3) 
1.2 
(0.6-2.3) 
1.4 
(1.0-1.9) 
2.0 
(1.0-4.0) 
1.4 
(0.8-2.2) 
1.2 
(0.7-2.0) 
1.7 
(1.0-3.0) 
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 ...CONTINUED 
 Cancer site in the proband 
 OP RP Esophagus Stomach CR Liver Pancreas Larynx Breast
b 
Edometrium
 b
 Ovary
 b
 Prostate Renal cell 
              
FH             
Ovary 
0.7 
(0.1-3.4) 
0.7 
(0.1-7.6) 
1.4 
(0.1-15.8) 
NE 
2.1 
(1.0-4.2) 
9.7 
(0.3-367.7) 
1.7 
(0.1-22.3) 
2.6 
(0.5-13.9) 
1.7 
(0.8-3.4) 
3.3 
(0.6-17.0) 
7.4 
(3.3-16.6) 
7.4 
(1.4-38.2) 
4.1 
(0.9-18.2) 
Prostate 
0.9 
(0.4-2.1) 
2.4 
(0.7-7.6) 
0.9 
(0.3-2.8) 
0.7 
(0.2-2.7) 
1.6 
(1.0-2.4) 
1.7 
(0.5-6.3) 
0.7 
(0.3-2.0) 
1.2 
(0.5-2.6) 
1.6 
(1.1-2.4) 
1.4 
(0.6-3.3) 
1.1 
(0.6-2.0) 
3.9 
(2.4-6.2) 
1.7 
(0.9-3.2) 
Bladder 
1.0 
(0.4-2.5) 
NE NE 
0.3 
(0.0-2.8) 
1.2 
(0.7-2.0) 
2.6 
(0.5-13.2) 
0.9 
(0.2-5.2) 
0.8 
(0.2-2.5) 
1.2 
(0.8-1.9) 
3.0 
(0.8-10.7) 
0.9 
(0.4-1.9) 
3.4 
(1.6-7.3) 
0.9 
(0.3-2.4) 
              
Kidney 
0.1 
(0.0-0.6) 
1.3 
(0.3-6.3) 
0.5 
(0.0-5.4) 
NE 
1.6 
(0.9-3.0) 
0.8 
(0.1-5.5) 
2.1 
(0.4-10.5) 
2.9 
(0.9-9.1) 
1.4 
(0.8-2.4) 
4.2 
(1.0-16.5) 
1.7 
(0.6-4.6) 
3.4 
(1.2-9.4) 
4.2 
(1.8-9.8) 
              
Brain 
1.0 
(0.5-2.0) 
1.8 
(0.6-6.1) 
1.5 
(0.5-4.3) 
1.4 
(0.3-8.1) 
1.4 
(0.9-2.1) 
1.0 
(0.2-4.9) 
2.2 
(0.8-6.1) 
0.8 
(0.3-1.8) 
1.2 
(0.7-1.8) 
4.2 
(1.3-13.3) 
0.8 
(0.4-1.6) 
1.1 
(0.6-2.1) 
1.4 
(0.7-2.7) 
              
All HLP 
cancers
e
 
1.0 
(0.6-1.8) 
1.2 
(0.4-3.3) 
0.7 
(0.2-2.0) 
0.8 
(0.2-2.4) 
1.4 
(1.0-2.0) 
0.5 
(0.1-2.9) 
0.8 
(0.3-2.1) 
1.1 
(0.6-2.2) 
1.7 
(1.2-2.4) 
1.2 
(0.5-2.8) 
1.6 
(1.0-2.5) 
1.1 
(0.6-1.9) 
1.4 
(0.8-2.5) 
              
All sites 
1.2 
(1.0-1.5) 
1.2 
(0.8-1.7) 
1.2 
(0.9-1.5) 
1.3 
(1.0-1.8) 
1.6 
(1.4-1.8) 
1.5 
(1.0-2.2) 
1.4 
(1.0-1.9) 
1.3 
(1.1-1.6) 
1.6 
(1.4-1.7) 
1.5 
(1.2-2.0) 
1.6 
(1.4-1.9) 
1.6 
(1.3-1.8) 
1.4 
(1.2-1.7) 
excluding  
cancer index
 
1.1 
(0.9-1.3) 
1.2
f 
(0.8-1.7) 
1.1 
(0.8-1.5) 
0.9 
(0.7-1.3) 
1.2 
(1.1-1.4) 
1.1 
(0.7-1.6) 
1.3 
(1.0-1.8) 
1.2 
(1.0-1.4) 
1.2 
(1.1-1.4) 
1.4
g 
(1.0-1.9) 
1.5 
(1.2-1.7) 
1.3 
(1.1-1.5) 
1.3 
(1.1-1.6) 
              
Abbreviations: OP, oral cavity and pharynx; RP, rhinopharynx, CR, colorectum; HLP, hemolymphopoietic; SCCE, squamous cell carcinoma of the esophagus. 
a
 Adjusted for age, sex (when appropriate), study centre (when appropriate), year of interview, education, body mass index, alcohol drinking, tobacco smoking, and 
number of brothers and sisters. Reference category: no family history of the selected cancer. 
b 
Further adjusted for menopausal status, age at menopause, oral 
contraceptive and hormone replacement therapy use, parity. Odds ratios for breast cancer were further adjusted for age at first birth. 
c 
Including rhinopharyngeal 
cancer. 
d 
Including cancer of the cervix, endometrium and uterus not otherwise specified. 
e
 Including Hodgkin lymphoma, Non Hodgkin lymphoma or unspecified, 
leukemia and myeloma. 
f
 Odds ratio for family history of all cancer sites, excluding cancer of the oral cavity and pharynx. 
g
 Odds ratio for family history of all 
cancer sites, excluding cancer of the uterus. 
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Table 4. Odds ratios
a
 (ORs) and 95% confidence intervals (CIs) of cancer at 13 different sites according to family history of selected cancers by sex 
and age at diagnosis
b
 of the affected first-degree relative. Italy and Switzerland, 1991-2009. 
 
 Male Female  <60 years ≥60 years 
FH, cancer site in relatives ca:co OR (95% CI) ca:co OR (95% CI)  ca:co OR (95% CI) ca:co OR (95% CI) 
Cancer site in the proband: Oral cavity/pharynx          
Oral cavity/pharynx 50:37 3.1 (1.8-5.1) 3:10 0.8 (0.2-3.8)  25:16 3.1 (1.4-6.6) 20:23 2.1 (1.0-4.5) 
Larynx 29:24 3.1 (1.6-6.0) 5:2 7.0 (0.7-66.7)  15:11 3.7 (1.4-9.7) 15:13 3.1 (1.2-7.7) 
Any site 308:599 1.3 (1.1-1.59) 204:453 1.2 (1.0-1.5)  203:371 1.4 (1.1-1.8) 227:497 1.2 (1.0-1.5) 
excluding oral cavity/pharynx 258:562 1.1 (0.9-1.4) 201:443 1.2 (0.9-1.5)  178:355 1.3 (1.0-1.6) 207:474 1.1 (0.9-1.4) 
Cancer site in the proband: Rhinopharynx          
Oral cavity/pharynx 2:5 1.3 (0.2-7.8) 1:1 1.4 (0.1-17.2)  2:2 2.7 (0.3-26.3) 1:3 0.9 (0.1-10.7) 
Colorectum 7:8 4.0 (1.3-12.2) 5:9 0.5 (0.1-1.7)  10:14 3.1 (1.3-7.6) 12:17 3.1 (1.4-7.0) 
Any site 51:116 1.4 (0.9-2.2) 28:96 0.9 (0.5-1.4)  32:92 1.1 (0.7-1.8) 42:91 1.5 (1.0-2.4) 
excluding oral cavity/pharynx 49:111 1.4 (0.9-2.2) 27:95 0.9 (0.5-1.4)  30:90 1.0 (0.6-1.7) 41:88 1.5 (0.9-2.4) 
Cancer site in the proband: SCCE          
Esophagus 10:12 1.6 (0.5-4.9) 2:2 1.9 (0.2-16.9)  6:7 1.3 (0.4-5.2) 6:7 2.1 (0.5-9.2) 
Oral cavity/pharynx 17:11 3.8 (1.5-9.7) 5:1 7.6 (0.5-109.9)  11:5 4.1 (1.3-12.9) 8:7 2.8 (0.7-11.2) 
Any site 124:229 1.3 (0.9-1.7) 72:158 1.2 (0.8-1.7)  75:155 1.2 (0.8-1.8) 93:209 1.1 (0.8-1.5) 
excluding esophagus 114:217 1.2 (0.9-1.7) 70:156 1.2 (0.8-1.7)  69:148 1.2 (0.8-1.8) 87:202 1.0 (0.7-1.5) 
Cancer site in the proband: Stomach          
Stomach 17:18 2.7 (1.3-5.5) 13:13 2.6 (1.2-5.9)  8:5 4.4 (1.4-14.2) 9:19 1.3 (0.6-2.9) 
Any site 62:136 1.3 (0.9-1.9) 48:101 1.3 (0.9-2.0)  36:74 1.4 (0.9-2.3) 36:91 1.1 (0.7-1.7) 
excluding stomach 45:118 0.9 (0.6-1.4) 35:88 1.0 (0.6-1.5)  28:69 1.3 (0.8-2.0) 27:72 0.9 (0.6-1.5) 
Cancer site in the proband: Colorectum          
Colorectum 129:79 3.5 (2.6-4.7) 101:93 2.2 (1.7-3.0)  197:119 3.5 (2.7-4.4) 206:134 3.2 (2.6-4.1) 
Any site 604:945 1.6 (1.4-1.8) 470:720 1.6 (1.4-1.8)  432:726 1.5 (1.3-1.8) 536:828 1.6 (1.4-1.8) 
excluding colorectum 475:866 1.3 (1.1-1.4) 369:627 1.3 (1.1-1.5)  335:656 1.2 (1.0-1.4) 379:722 1.2 (1.0-1.3) 
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 ...CONTINUED   
 Male Female  <60 years ≥60 years 
FH, cancer site in relatives ca:co OR (95% CI) ca:co OR (95% CI)  ca:co OR (95% CI) ca:co OR (95% CI) 
Cancer site in the proband: Liver          
Liver 15:10 3.6 (1.4-9.1) 8:8 1.1 (0.5-2.3)  9:9 3.6 (1.2-11.4) 7:8 1.7 (0.5-5.6) 
Any site 60:113 1.5 (0.9-2.4) 41:89 1.4 (0.8-2.4)  33:78 1.4 (0.8-2.5) 45:105 1.2 (0.7-2.0) 
excluding liver 45:103 1.1 (0.7-1.8) 33:81 1.1 (0.6-1.9)  24:69 1.0 (0.5-1.8) 38:97 1.0 (0.6-1.7) 
Cancer site in the proband: Pancreas          
Pancreas 6:11 1.1 (0.4-3.5) 4:4 2.0 (0.4-8.8)  3:3 1.7 (0.3-9.6) 6:11 1.3 (0.4-3.9) 
Stomach 16:11 3.5 (1.5-8.1) 6:10 1.4 (0.4-4.3)  7:7 2.3 (0.7-7.5) 11:10 2.3 (0.9-5.9) 
Any site 113:165 1.5 (1.1-2.1) 77:128 1.3 (0.9-1.9)  79:113 1.6 (1.1-2.3) 84:149 1.2 (0.9-1.8) 
excluding pancreas 107:154 1.5 (1.1-2.1) 73:124 1.2 (0.8-1.8)  76:110 1.6 (1.1-2.3) 78:138 1.2 (0.8-1.7) 
Cancer site in the proband: Larynx          
Larynx 24:23 2.7 (1.4-5.3) 5:4 3.2 (0.7-14.0)  15:13 3.6 (1.5-8.8) 10:16 1.3 (0.5-3.2) 
Skin 3:3 4.8 (0.7-31.9) 4:0 ∞  3:2 3.2 (0.4-26.5) 5:1 23.5 (2.2-248.3) 
Any site 217:402 1.4 (1.1-1.8) 164:301 1.4 (1.1-1.8)  142:256 1.4 (1.1-1.8) 185:367 1.2 (1.0-1.6) 
excluding larynx 193:379 1.3 (1.0-1.6) 159:297 1.3 (1.0-1.7)  127:243 1.2 (0.9-1.6) 175:351 1.2 (0.9-1.5) 
Cancer site in the proband: Breast
 d
          
Breast 1:3
c 
- 310:143 2.6 (2.1-3.2)  213:93 2.7 (2.1-3.4) 92:52 2.2 (1.5-3.1) 
Colorectum 73:54 1.5 (1.0-2.1) 82:61 1.5 (1.1-2.2)  109:79 1.6 (1.2-2.1) 120:81 1.7 (1.2-2.2) 
Skin 18:2 10.7 (2.4-46.9) 8:8 1.0 (0.4-2.8)  15:2 10.2 (2.3-45.8) 11:8 1.3 (0.5-3.2) 
Prostate 59:42 1.6 (1.1-2.4) - -  8:5 2.2 (0.7-6.8) 51:35 1.6 (1.0-2.5) 
All HLP
 e
 57:38 1.7 (1.1-2.6) 36:20 1.8 (1.1-3.2)  55:30 2.0 (1.3-3.2) 34:26 1.4 (0.8-2.4) 
Any site 709:663 1.3 (1.2-1.5) 754:528 1.9 (1.6-2.1)  654:536 1.6 (1.4-1.8) 723:590 1.5 (1.4-1.8) 
excluding breast 709:663 1.3 (1.2-1.5) 444:385 1.4 (1.2-1.6)  441:443 1.2 (1.0-1.3) 631:538 1.3 (1.2-1.5) 
Cancer site in the proband: Endometrium
 d
          
Uterus - - 19:25 2.0 (1.0-4.0)  18:22 2.1 (1.0-4.2) 4:8 1.6 (0.4-6.5) 
Brain 5:5 3.5 (0.9-14.7) 5:2 5.8 (0.8-42.9)  4:3 2.9 (0.5-15.7) 4:4 5.0 (1.0-24.9) 
Any site 96:190 1.4 (1.0-2.0) 92:136 1.8 (1.2-2.5)  78:126 2.1 (1.4-3.0) 86:151 1.6 (1.1-2.3) 
excluding uterus 96:190 1.4 (1.0-2.0) 73:111 1.6 (1.1-2.3)  65:109 1.9 (1.3-2.8) 82:143 1.5 (1.0-2.1) 
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Abbreviations: Ca, cases; Co, controls; OR, odds ratio; CI, confidence interval; HLP, hemolymphopoietic; SCCE, squamous cell carcinoma of the 
esophagus.
 
a
 Adjusted for age, sex (when appropriate), study centre (when appropriate), year of interview, education, body mass index, alcohol drinking, tobacco 
smoking, and number of brothers and sisters. Reference category: no family history of the selected cancer. 
b 
The sum of cases and controls across 
strata may not add to the total because of some missing values of age at cancer diagnosis in relatives. 
c 
First-degree male relatives with history of male 
breast cancer. 
d 
Further adjusted for menopausal status, age at menopause, oral contraceptive and hormone replacement therapy use, parity. Odds 
ratios for breast cancer were further adjusted for age at first birth. 
e
 Including Hodgkin lymphoma, Non Hodgkin lymphoma or unspecified, leukemia 
and myeloma 
  ...CONTINUED   
 Male Female  <60 years ≥60 years 
FH, cancer site in relatives ca:co OR (95% CI) ca:co OR (95% CI)  ca:co OR (95% CI) ca:co OR (95% CI) 
          
Cancer site in the proband: Ovary
 d
          
Ovary - - 27:9 7.4 (3.3-16.6)  17:6 7.3 (2.7-19.6) 10:3 7.5 (1.9-29.9) 
Colorectum 29:44 1.6 (0.9-2.7) 33:48 1.6 (1.0-2.7)  54:57 2.1 (1.4-3.2) 50:65 1.8 (1.2-2.7) 
Breast 1:6
c 
- 103:106 2.4 (1.8-3.2)  72:67 2.6 (1.8-3.8) 31:47 1.6 (1.0-2.7) 
Any site 275:550 1.4 (1.2-1.7) 282:392 2.1 (1.2-1.8)  276:411 1.9 (1.6-2.4) 233:467 1.4 (1.2-1.8) 
excluding ovary 275:550 1.4 (1.2-1.7) 255:383 1.8 (1.5-2.2)  259:405 1.8 (1.4-2.2) 223:464 1.3 (1.1-1.6) 
Cancer site in the proband: Prostate          
Prostate 90:28 3.9 (2.4-6.2) - -  11:4 4.8 (1.3-17.0) 75:23 3.9 (2.3-6.6) 
Lung 88:72 1.4 (1.0-2.1) 27:17 1.6 (0.8-3.2)  3:2 1.7 (0.2-13.2) 70:50 1.4 (0.9-2.1) 
Ovary - - 10:2 7.4 (1.4-38.2)  7:2 6.0 (1.1-33.4) 2:0 ∞ 
Bladder 9:22 2.5 (1.0-5.8) 12:1 11.3 (1.4-90.8)  7:2 2.4 (0.5-12.1) 21:8 3.3 (1.4-7.9) 
Kidney 11:4 3.2 (1.0-10.7) 5:2 3.9 (0.6-25.9)  5:3 2.7 (0.5-13.0) 11:3 4.0 (1.0-15.5) 
Any site 400:337 1.6 (1.3-2.0) 301:256 1.5 (1.2-2.8)  269:242 1.6 (1.3-2.0) 389:297 1.7 (1.4-2.0) 
excluding prostate 310:309 1.2 (1.0-1.5) 301:256 1.5 (1.2-2.8)  258:238 1.4 (1.1-1.8) 314:274 1.3 (1.1-1.6) 
Cancer site in the proband: Renal cell          
Kidney 8:5 2.9 (0.9-9.4) 10:3 6.2 (1.7-22.9)  9:4 4.3 (1.3-14.5) 8:2 7.6 (1.6-36.7) 
Any site 206:324 1.5 (1.2-1.8) 175:259 1.5 (1.2-1.9)  145:234 1.5 (1.2-1.9) 182:284 1.5 (1.2-1.9) 
excluding kidney 198:319 1.4 (1.1-1.7) 165:256 1.4 (1.1-1.8)  136:230 1.4 (1.1-1.8) 174:282 1.4 (1.1-1.8) 
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Table 5. Odds ratios (OR) of laryngeal cancer and corresponding 95% confidence intervals 
(CI) according to family history of laryngeal cancer in first degree relatives in strata of selected 
covariates. 
 
 Family history of laryngeal cancer 
 Cases:Controls 
OR
a 
(95% CI) OR
b 
(95% CI) 
 No Yes 
     
Age (years)     
< 60 341:820 14:13 2.8 (1.3-6.7) 3.5 (1.4-8.8) 
≥ 60 482:1123 15:14 2.3 (1.1-4.9) 2.3 (1.0-5.5) 
 
Smoking status
c 
 
   
Never/ex smokers 304:1441 12:22 2.8 (1.3-5.9) 2.5 (1.1-5.7) 
Current smokers 519:497 17:5 3.3 (1.2-9.0) 3.5 (1.2-10.0) 
 
Alcohol (drinks/week)
c 
 
   
< 28 303:1355 8:17 2.2 (0.9-5.3) 2.3 (0.9-6.4) 
≥ 28 514:583 20:10 2.8 (1.3-6.1) 3.0 (1.3-7.0) 
     
1 
Estimates from logistic regression models, adjusted for age, sex and center. Reference category: 
no family history. 
2 
Further adjusted for education, tobacco smoking, alcohol drinking and number of brothers and 
sisters.  
3
 The sum does not add up to the total because of some missing values.
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Figure 1. Odds ratios (OR)
a
 and 95% confidence intervals (CI) for laryngeal cancer according to 
alcohol drinking, tobacco smoking and family history of laryngeal cancer in first-degree relatives.  
No
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45
50
<28 drinks, 
never/ex smokers <28 drinks, 
current smokers ≥28 drinks,
never/ex smokers ≥28 drinks, 
current smokers
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18.2
(13.7-24.2)
1.4
(0.3-6.2)
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(4.8-129.1)
13.9
(5.1-38.1)
37.1
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Family history
of laryngeal cancer
Odds ratio
Alcohol and smoking habits
 
 
a
 Adjusted for age, sex, study center, education and number of brothers and sisters. 
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Figure 2. Odds ratios (OR)
a
 and 95% confidence intervals (CI) for liver cancer according to 
HBsAg and/or anti-HCV positivity and family history of liver cancer in first-degree relatives.  
 
0
>=1
0
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40
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80
1
38.19
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(0.94-9.21)
72.48
(21.92-239.73)
Number of first-
degree relatives 
with liver cancer
OR
0
>=1
No
Yes
HBsAg and/or anti-HCV positivity
 
 
 
 
Abbreviations: HBsAg, hepatitis B surface antigen; anti-HCV, antibodies against hepatitis C virus. 
 
a
 Adjusted for age, sex, centre, education, alcohol drinking and smoking habits. 
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Table 6. Main characteristics of the studies on liver cancer and family history of liver cancer included in the meta-analysis 
 
Study Country Gender 
No. of 
Cases 
No. and type 
of controls / 
size of Cohort 
Years of study/ 
duration of 
follow-up 
Adjusting factors and 
matching variables 
 
Notes 
Case-control 
studies 
        
Tsukuma et al, 
1990 [37] 
Japan Both 229 266 hb 1983-87 Age, sex, alcohol, smoking, 
history of blood transfusion, 
HBsAg 
  
Chen et al, 
1991 [38] 
Taiwan Male 200 200 pb 1985-87 Age, sex, ethnic group, 
residence, alcohol, smoking, 
HBsAg/HBeAg 
 95% CI for the adjusted OR was 
calculated on the distribution of 
cases and controls according to FH 
of liver cancer 
Tanaka et al, 
1992 [36] 
Japan Both 204 410 pb 1985-89 Age, sex   
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Fernandez et 
al, 1994 [41] 
Italy Both 320 1408 hb 1983-92 Age, sex, residence, 
education, alcohol, smoking, 
history of cirrhosis and 
hepatitis 
  
Donato et al, 
1999 [40] 
Italy Both 287 450 hb 1996-98 Age, sex, date of admission to 
hospital, residence, education, 
alcohol, HCV and HBV 
infection, FH of all cancer 
excluding liver  
  
Zhu et al, 
2005 [42] 
China Both 246 549 hb 2001-03 Age, sex  OR and 95% CI calculated on the 
distribution of cases and controls 
according to FH of liver cancer 
Hsu et al, 
2006 [43] 
Taiwan Both 225 225 hb 1999-2001 Age, sex, alcohol, TCR-γ STR 
genotype 16  
 Cases were HBV- or HCV-related 
cirrhotic patients with HCC; controls 
were HBV- or HCV-related cirrhotic 
patients without HCC 
Hassan et al, 
2009 [39] 
USA Both 347 1075 pb 2000-08 Age, sex, ethnic group, 
education, alcohol, smoking, 
diabetes, anti-HCV, HBsAg, 
anti-HBc 
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Turati et al, 
2011 (present 
study) 
Italy Both 229 431 hb 1999-2002 age, sex, centre, education, 
alcohol, smoking, HBsAg 
and/or anti-HCV 
 
  
Cohort studies  
        
Sun et al, 1999 
[46] 
China Male 22 145 pr 1988-98 
10 years 
Age, aflatoxin, anti-HCV  The cohort consisted of men with 
chronic HBV hepatitis. 
Yu et al, 2000 
[44] 
Taiwan Male 132 4808 pr 1988-92 
8.9 years 
(average) 
Age, education, alcohol, 
smoking, number of siblings 
 The cohort consisted of men HBV 
carriers. 
The paper reports also data from a 
case-control familial study. 
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Chen et al, 
2002 [45] 
Taiwan Both 94 4843 pr 1991-98 
7 years 
(average) 
Age, sex, HBsAg, HCV, AFP, 
AST, ALT 
 The cohort consisted of subjects 
selected among members of a 
screened population who were 
positive for at least one of 6 
investigated risk factors of HCC (i.e., 
HBsAg, anti-HCV, AFP≥20 ng/mL, 
AST≥40 IU/L, ALT≥45 IU/L and 
family history of HCC). I selected 
ORs for incidence rather than 
mortality. 
Evans et al, 
2002 [45] 
China Both 1092 83,794 pr 
434,718 py 
1992-2000 
8 years 
Males: age, occupation, 
alcohol, tea, well water, 
history of acute hepatitis, 
HBsAg 
Females: age, alcohol, 
smoking, history of acute 
hepatitis, HBsAg 
 The paper reports results from a 
cohort of males and one of females; 
results were stratified by sex. 
The outcome was death for HCC 
Abbreviations: hb, hospital-based controls; pb, population-based controls; pr, persons at risk; py, person-years; HBsAg,  hepatitis B surface antigen; HBeAg, 
hepatitis B e antigen; CI, confidence interval; OR, odds ratio; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; anti-HCV, 
antibodies against hepatitis C virus; anti-HBc, hepatitis B core antibody; AFP,  alpha-fetoprotein; AST,  aspartate transaminase; ALT,  alanine transminase. 
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Figure 3. Forest plot for the association between family history of liver cancer and liver cancer risk. 
 
Abbreviations: RR, relative risk; CI, confidence intervals; M, males; F, females. 
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Chapter 2 
A new approach: family history scores 
 
 
2.1 Introduction on family history scores 
Estimates of disease RR in families have important utilities in investigations of disease 
etiology. They are used to examine whether the disease of interest clusters in certain 
families and whether its etiology has a familial component. They are also used to adjust 
for familial aggregations when evaluating the effects of other non-familial etiologic 
factors in epidemiologic studies. Furthermore, familial RR estimates are used to 
examine effect modification of an etiologic factor according to levels of disease relative 
risk in families. Finally, a valid assessment of familial RR may have important clinical 
utility in triaging persons for more involved genetic screening and informing family 
members about potential risks. 
FH scores are used for estimating the familiar risk (FR), that is the level of risk for a 
particular disease among members of that family. A strong association between FH and 
the risk of a disease is not a proof of the genetic basis for the disease, since both genetic 
and environmental factors influenced this risk level. However, these measures can be 
useful as proxies of a genetic transmission of the disease when there are no genetic tests. 
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FH scores are created from reports about the disease status of the relatives of a family 
and can be regarded as an estimate of FR, or a measure of FR that is prone to 
measurement error. 
A good score should have some desirable properties: 
• a score should consider the risk profile of a family, taking into account the risk 
profile of each relative in terms of relevant covariates (age, sex, smoking status 
and so on). For example, because early onset is often characteristic of familial 
cases of disease, such families should have a higher score.  
• a score should be robust to family size and time at risk, not changing 
systematically with the number of relatives. Families with the same proportion 
of relatives affected should have a similar score;  
• a score should consider relationship of relatives, close blood relatives being 
given more weight. 
• a score should not be inflated by a single individual; small families are 
particularly vulnerable to the influence of a single affected member.  
Some definitions before to go through the different formulations of the FH scores: 
- Disease status of the relative: It was determined by the reported lifetime disease status 
or cause of death. For the relative i (i=1,…, jn  , where jn  is the family size of family j) 
in family j (j=1,…,n, where n is the number of subjects included in the study), the 
disease status is referred to 
ji
o , where
ji
o  =1 if affected and 0 if not affected. Thus, jo  
represents the number of affected relatives in family j. 
- Time at risk: For each relative it was defined as age at diagnosis if diseased, current 
age if not diseased and alive, or age at death if unaffected and deceased. Each individual 
contributed only with his/her disease-free life experience. 
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- The expected risk of disease: The expected risk of disease for relative i in the family j 
is referred to 
ji
e  (thus, je  represents the total expected number of affected relative in 
family j). Usually, the expected risk for each relative comes from an external source 
according to strata of important risk factors like age and gender. In particular the 
expected risk for each family member is obtained by multiplying age-, sex-, and time-
specific incident rates for the disease in the area under study (taken from, e.g., regional 
registries) by age-, sex-, and birth cohort-specific person-years at risk. Person-years at 
risk, as it was mentioned before, were accumulated until age at interview or age at death 
for people without the disease or age at diagnosis for people with a history of the 
disease. In our knowledge, only a FH score, which will be called “FHS2” from this 
point on, calculates the expected risk of disease from internal data, using a logistic 
regression model fitted in a dataset in which all the probands’ relatives are combined. 
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2.2 Review of the family history scores 
Table 7 shows results from a review of the literature on FH measures, which let me 
identify 13 different FH scores, including the binary indicator and the number of 
affected relatives [227-236]. They have been used in heterogeneous settings and for 
different study designs and topics. Besides the “binary indicator” and the “number of 
affected relatives”, largely used in the medical literature, most of the more complex FH 
scores have been proposed for common diseases, in particular for coronary heart 
diseases.  
The most common FH score in use is the dichotomous measure, defined to be positive 
in families that have at least one relative with the disease. Another summary that carries 
a little more information is the number of affected family members. These crude 
summaries have two critical deficiencies in view of their use as familial relative risk 
estimates. First, they do not account for family size, structure, or ages of family 
members. Larger families and families with older members are naturally more likely to 
have members who had developed chronic diseases such as cancer. Second, the 
summaries do not take chance into account: families with identical familial relative risk 
levels, sizes, structures, and ages can yield different numbers of affected members by 
chance alone. The proportion of affected relatives is still a simple summary measure 
with the advantage to taking into account the size of the family (but not its structure in 
term of age, and sex of its members).   
The others FH scores proposed in the literature are statistics that describe the deviation 
from the expected risk for each family. Briefly, the bigger is the difference between the 
observed and the expected situation in a family, the bigger is the FH score of that family 
(i.e., greater is the estimate of the FR), in absolute value. Some FH scores are 
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aggregated scores (Slack and Evans’s score, Fain and Goldar’s score, Lynch’s score, 
Reed’s score, Kee’s score): they use the total expected ( je ) and the total observed ( jo ) 
number of affected relatives in a family (j). Non-aggregated scores (Chakraborty’s 
score, Schwartz’s score, Groenelved and Hitzeroh’s score, FHS1 and FHS2), instead, 
link the observed status (
ji
o ) to the expected risk of disease (
ji
e ) for each proband’s 
relative; they are therefore sensitive to which relative has the disease. Non-aggregated 
scores are more sensitive to the risk profile of the affected relatives, comparing the 
observed status to the expected risk of each relative separately. In general, an affected 
relative at low risk of disease contributes a large positive value to the non-aggregate 
score; conversely, a high-risk affected relative gives only a small contribution. If 
unaffected, the negative contribution of high risk relatives is greater than that of low-
risk relatives. The main deficiency of a non-aggregated score is that it tends to be 
unstable in small families, i.e. such scores enable a low risk (e.g. young) affected 
relative to inflate the score when the number of relatives is small. 
The expected risk of disease for each family member (or the expected number of 
affected relatives in a family) is usually estimated by using a set of external reference 
rates for the disease, on strata of age, sex, and possibly other risk factor of the disease. 
These scores, therefore, take into account the structure of the family in terms of age, 
sex, and other factors when possible. 
When no affected relative is observed in a family, Slack and Evans’s score, comparable 
to the standardised mortality ratio (SMR), is zero and Lynch’s score is equal to -1; 
Chakraborty’s score is always positive defined; FHS1 differs from Schwartz’s score in 
dividing by jn , thus adjusting for family size.  
FHS2 merits a separate discussion: proposed by Silberberg et al [235], together with 
FHS1, this score does not use external data to estimate the expected risks of disease in 
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relatives. It estimates them from a logistic regression model, in which all subjects’ 
relatives were combined in a dataset and their disease status (1 if the relative had had 
the disease under investigation, 0 otherwise) is fitted as a function of their sex, age and 
other risk factor for the disease. Expected probability of disease estimated by this model 
represents the expected risk of disease that is then compared to the observed relatives’ 
status. The residuals from this model are then averaged over each family to form FHS2.  
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2.3 Family history score comparison: Methods 
I made a comparison of several FH scores using two different complementary 
approaches. Firstly, I’ve used a data-derived approach, applying each identified FH 
score on the Italian HI-WATE study on colorectal cancer, with the aim of examining the 
power of different FH scores in predicting colorectal and liver cancer, respectively. In 
that observational study, cases and controls were asked to report selected information 
(e.g., age and sex) of both affected and unaffected relatives; this allowed me the 
calculation of the values of the various FH scores for each study participant. The 
comparison of the FH scores was also performed using a simulation approach. In this 
situation the gold standard, i.e., the true disease risk in the family (i.e., the FR), is a 
known quantity. Thus, the performance of FH scores may be evaluated relative to the 
true FR. In brief, the research question was: how well does a FH score predict whether a 
family is at high or low risk? A simple situation in which the level of diseases risk is 
dichotomous and families may be classified as either high or low risk was assumed. 
 
2.3.1 Data-derived approach  
2.3.1.1 The Italian HI-WATE study 
HI-WATE data derive from a case-control study of colorectal cancer conducted 
between 2007 and 2010 in the greater Milan area and in the provinces of Pordenone and 
Udine, Northern Italy, and in the province of Barcelona, Spain. In the current analysis, 
only Italian data were analyzed. 
Cases were 474 subjects aged 20-85 years with a diagnosis of incident, histologically 
confirmed colon or rectal cancer and with no previous diagnosis of cancer. They were 
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identified in major general and teaching hospitals in the study areas (Ospedale 
Niguarda, Istituto Nazionale dei Tumori, Istituto Europeo di Oncologia, Policlinico di 
Monza, Ospedale Fatebene Fratelli, Milan; Centro di Riferimento Oncologico, Ospedale 
S. Maria degli Angeli, Pordenone; S. Maria della Misericordia, Udine). Identification of 
new cases was achieved through periodical visits to the hospital departments where 
cases were diagnosed or treated. The local coordinator kept a record of all cases 
identified, of those who refused participation, and indicated the reasons for refusal of 
interview or blood sample collection.  
Controls were 561 subjects with no previous diagnosis of cancer, randomly chosen 
among subjects admitted as in-patients or out-patients in the same hospital as cases for 
acute, non chronic diseases, unrelated to alcohol, tobacco or dietary habits nor to known 
or potential risk factors for colorectal cancer. Diseases of controls mainly included 
traumas; minor surgical interventions (i.e., appendectomy, hernia, etc.) and 
genitourinary, skin, subcutaneous tissue, musculoskeletal, peripheral arterial or venous, 
ear, eye and mastoid disorders, with a proportion of controls within a specific diagnostic 
group not over 33% of the overall group. An interviewer contacted the individuals to 
schedule an appointment, asked for the consent and did the interview and blood 
collection. 
A questionnaire similar to that used in the network of case-control studies was 
administered to both cases and controls. The FH section was however more detailed 
than that in the questionnaire of network of case-control studies, and therefore allowed 
the construction of the various FH scores. Besides the number of brothers, sisters, sons, 
and daughter, for each FDR (parents, siblings, and children), whether affected or 
unaffected by cancer, the vital status, current age/age at death, history of cancer 
(excluding non-melanoma skin cancer), site of cancer, and age at diagnosis were 
 61 
 
recorded. A specific section of the questionnaire included detailed information on water 
consumption and water-related habits in order to evaluate the long-term exposure to 
various disinfection by-products through ingestion, inhalation and dermal absorption. 
However, this information was not used in the current analyses.  
The study protocols have been submitted to approval by the local ethics committees, 
and, during the study, national and international directives were followed (deontological 
code, Helsinki declaration). A signed informed consent to participate were obtained 
from all study subjects prior participation. An identification code were assigned to all 
cases and controls at the study entry and databases including information from 
interview and biological samples contained only the code of the subject. The code 
assigned to the subject and the personal information was kept on a separate file in a 
different computer.  
Table 8 shows the main characteristic of cases and controls. 
 
2.3.1.2 Family history score calculation 
The detailed information of FH of cancer that was collected allowed for the construction 
of different FH scores. Colorectal cancer risk among families was therefore measured 
using the following 13 FH scores:  
(1) Binary indicator  
(2) Number of affected relatives 
(3) Proportion of affected relatives  
(4) Slack and Evans’s score 
(5)  Chakraborty’s score 
(6)  Fain and Goldar’s score 
(7) Lynch’s score 
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(8) Reed’s score 
(9) Schwartz’s score 
(10) Groenelved and Hitzeroth’s score 
(11) Kee’s score 
(12) FHS1 
(13) FHS2; 
whose formulations and references are reported in Table 5.  
For each score, two different methods for the calculation of the expected risk of 
colorectal cancer in relatives were used: (a) a method which needs internal data only, 
and (b) a method requiring the incidence rates of the disease under investigation 
according to age, sex, and possibly other factors involved in the disease aetiology, in the 
area under study.  
In the following, a description of these methods. 
 
(a) Use of internal data only 
Methods: This approach for 
ji
e  calculation was proposed by Silberberg et al. (13) in 
1999, when introducing FHS2. This method does not require external data on the 
expected risk of disease in the population since 
ji
e  are estimated directly from the 
dataset. This is a one of its advantage, but it could also be a disadvantage since there is 
no validation versus external data. Briefly, in order to estimate the expected risk of the 
disease for each relative, his/her disease status (affected, if had the disease; not affected 
otherwise) was fitted as a function of his/her sex, age, and possibly other potential risk 
factors for the disease (if available), using a logistic regression model. In this model, 
age represents the disease-free life experience of each relative, and is defined as age at 
diagnosis for relatives affected by the disease, current age for those free of the disease 
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and alive, and age at death for those unaffected by the disease and deceased. For each 
relative in the dataset, the probability predicted from the model represents his/her the 
expected risk of disease (for relative i in the family j is referred to as
ji
e ).  
Application: In the Italian HI-WATE study the only information on potential risk 
factors for colorectal cancer recorded in relatives were age and sex. I therefore 
combined all the FDR (n=6538) of the study subjects’ in a unique dataset; then their 
disease status (1 if the relative had a history of colorectal cancer, 0 otherwise) was fitted 
as a function of their age (in continuous) and sex, using a logistic regression model. Age 
was defined as age at diagnosis for FDR with a history of colorectal cancer (regardless 
of their vital status at the time of data collection), current age for those without a history 
of colorectal cancer and alive, and age at death for those unaffected by colorectal cancer 
and deceased. 
 
(b) Use of cancer registry information 
Methods: The most commonly method for calculating 
ji
e  presupposes the availability 
of the incidence rates for the disease under investigation according to age group, sex, 
time period, and possibly other potential risk factors for the disease (e.g, race and 
smoking).  
For the ith family's jth member, the expected risk ije  is given by the cumulative risk of 
the disease under observation: 
)*exp(1 
k
ijkkij te   
where k  is the external reference rate for the kth stratum (age, -sex-, and other factor-
defined stratum) and ijkt is the length of time that ith family's jth member spent under 
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observation in the kyh stratum. Ages and sex of the family members are therefore 
accounted for in the computation of the expected risk.  
Application: From the age- and sex-specific incidence rates of colorectal cancer from 
cancer registries of Varese 1998 (for study subjects from the great Milan area) and 
Friuli Venezia Giulia 1998-2002 (for study subjects from Pordenone and Udine), I 
therefore obtained the expected risk of colorectal cancer for each FDR in my dataset 
using the formula above. 
From the expected risks of colorectal cancer for each FDR, obtained from the two 
methods presented above (i.e., use of internal data only - use of external data) the value 
of the 13 FH scores was calculated for each family in the HI-WATE study. Except for 
the binary indicator, which contemplates only two possible alternatives (Yes/No), study 
subjects were divided into 3 different categories according to their value on each FH 
score. Subjects reporting no affected relative were included in the same category labeled 
“low”, since the interest was in the ORs comparing subjects with a positive FH (divided 
in two or more groups on the basis of FH scores) to those with no FH (i.e., no affected 
relatives in the family). Subjects with at least one relative affected by colorectal cancer 
were divided into two categories: the category labeled “intermediate”, included subjects 
with the FH score value lower than the median FH score calculated among controls with 
a positive score, and the category labeled “high”, included subjects with the FH score 
value greater than it. 
 
2.3.1.3 Statistical analysis 
Multiple logistic regression models were used to assess the association between a FH of 
colorectal cancer and colorectal cancer risk according to different methods to define FH 
of colorectal cancer, and to examine the goodness-of-fit and the accuracy of these 
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different methods in predicting the development of colorectal cancer. A series of 
multiple logistic regression models in which the outcome was the proband’s disease 
status (case/control) and the main explanatory variable was each of the FH score, 
together with the same set of covariates (age, sex, center and education, BMI, physical 
activity, tobacco smoking, alcohol drinking, and number of siblings) were fitted. The 
comparison between the different scores was made using the area under the curve 
(AUC) of the receiver operating characteristic (ROC) curve, ranging between 0.5 and 1, 
with higher values indicating better discrimination of cases and controls. The 
comparison between the AUCs of different FH scores with the AUC of the simple 
proportion was performed using a nonparametric approach for correlated ROC curves 
(i.e., model fitted on the same dataset) [237]. 
 
2.3.2 Simulation approach 
Assuming that FR is dichotomous, data of 1000 families with high risk and 1000 
families with low risk were simulated from a hypothetical population. Different 
scenarios were set: the proportion (π) of families with high risk in the population was 
chosen to be 0.0001, 0.001, 0.05, 0.10, 0.20, or 0.40 and RR of disease comparing high-
risk and low-risk individuals to be 1.2, 2.0, 3.0, 4.0. Then, FH data for each individual 
were generated: the number of family members was generated by a truncated Poisson 
distribution with mean 8.5 (average family size in the network of Italian and 
Switzerland case-control studies), truncated so that each individual had at least two 
relatives (the parents). Second, age of the family members (<45, 56-55, 56-65, >65) was 
generated according to a multinomial distribution with probabilities 0.1321, 0.2383, 
0.3352 and 0.2944 (these probabilities were derived from the age distribution of 
controls in the network of Italian and Switzerland case-control studies). For simplicity, 
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the gender of the subjects was ignored. The expected risks of disease for each family 
member ( ije ) were chosen to be 0.001, 0.01, 0.10 or 0.20 or 0.04, 0.08, 0.12, 0.16 for 
the four age strata, respectively. Then, assuming that the disease is not correlated with 
family size (i.e., the disease is not associated with the parental choice to for having 
additional children) and age stratum, the disease variable for each family member ( ijo ) 
was generated according to a Bernoulli distribution. The probabilities of disease 
depended on age stratum and FR, and were computed as follows: 
P(D | FR=low) = 
)1(1  RR
eij

, where D is the disease. 
This comes from the following equation: 
 *)/()1(*)/(
)(*)/()()|(
highFRDPlowFRDP
highFRPhighFRDPlowFRPlowFRDPeij


  
Rewriting P(D | FR=high)= P(M | FR=low)*RR 
)*1(*)/(
**)/()1(*)/(
RRlowFRDP
RRlowFRDPlowFRDPeij




 
And then: 
)1(1
)/(


RR
e
lowFRDP
ij

; consequently: P(D | FR=high) = RR* P(D | FR=low) 
Simulated data were analyzed using a logistic regression model for FR (dependent 
variable) on the 13 FH scores described earlier one by one (in continuous). For each 
setting, 200 simulations were conducted, and the mean and standard deviation of the 
AUC for each FH score were computed from the results. 
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2.4 Family history score evaluation: Results 
2.4.1 Data derived-approach 
(a) Expected risk of colorectal cancer in relatives 
Use of internal data only: Among the 6538 cases and controls’ FDR, 114 had had a 
history of colorectal cancer. The main results for the logistic regression model fitted on 
the relatives’ dataset (outcome: relatives’ colorectal cancer status; covariates: age (in 
continuous) and sex (Females/Males)) are reported in Table 9. The logistic regression 
estimated an OR of colorectal cancer of 1.02 (95% CI, 1.01-1.03) for every 1 year 
increase in age and an OR of 0.77 (95% CI, 0.53-1.13) for females, as compared to 
males (i.e., age =0.021, sex = -0.258).  
The predicted probabilities of colorectal cancer estimated from the regression 
coefficients are relatively small for each subject, ranging from a minimum of 0.0042 to 
a maximum of 0.0401, with a median value of 0.0173 and a standard deviation of 
0.0067.  
Use of external data: When the colorectal cancer incidence rates from registries in 
Varese and Friuli Venezia Giulia were used, the median value of the expected risk of 
colorectal cancer for FDR was 0.0167 with a standard deviation of 0.0307 
(minimum<0.00001 and maximum=0.1863). 
Figure 4 shows the distribution of the expected risk of colorectal cancer in FDR using 
both methods. When external data were used, the expected risk of disease has a skewed 
(skewed=1.506)  distribution with a long tail to the right of 0, which arises from the 
small expected values due to the low prevalence of the disease in the population. The 
distribution is also kurtotic (kurtosis=2.366), with "heavier tails" than for a normal 
distribution. The distribution of the expected risk of disease when internal data where 
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used is less asymmetrical (skewed=0.324) with slightly “lighter tails" than for a normal 
distribution.  
 
(2) FH scores 
Summary descriptive measures for the different FH scores (only the 11/13 continuous 
FH scores) by the two methods for expected risk calculation are presented in Table 10. 
Some of the FH scores reached values that exceed 100, other had maximum values in 
the order of some tens, others did not reach 10, and some others don’t exceed 1. For 
each score, the larger ranges were found when using the external data method, reflecting 
the distribution of the expected risk of colorectal cancer presented before (see Figure 4). 
Because of their formulations, some FH scores are always positive (i.e., proportion, 
Slack and Evans’ score, Chakraborty’s score), some others assume also negative values 
(i.e., Fain and Goldar’s score, Lynch’s score, Reed’s score, Schwartz’s score, Groenveld 
and Hitzeroth’s score, Kee’s score, FHS1 and FHS2). The form distribution is similar 
for each FH score, with the great part of the subjects (substantially those with no FH) 
characterized by the lowest scores and a small part of them (substantially those with a 
positive FH) characterized by relatively high values as compared to the others.  
Table 11 reports the joint distribution of the case-control study participants according to 
the FH scores categories and the observed number of FDR with colorectal cancer for 
both methods for expected risk calculation. For each score, the “low” category was 
constructed so that it includes subjects with no FH. With both methods (internal / 
external data), Slack and Evans’ score, Fain and Goldar’s score, Lynch’s score and 
Reed’s score classified study subjects in the same manner. When using the method of 
internal data only, the 10 study subjects reporting two or more relatives affected by 
colorectal cancer were classified in the “high” category for each FH score, with the only 
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exception of the Kee’s score, which classified 8 of these subjects in the “high” category 
and 2 in the “intermediate” one. When using the method requiring incidence rates of 
colorectal cancer, 6 scores (i.e., Chakraborty’s, Schwartz’s, Groenveld and Hitzeroth’s, 
and Kee’s score, FHS1 and FHS2) classified 9/10 subjects with two or more affected 
relatives in their “high” category and 1/10 of those subjects in their “intermediate” one. 
Chakraborty’s, Schwartz’s, and Groenveld and Hitzeroth’s scores, FHS1 and FHS2 (and 
not Kee’s score) classified these 10 subjects in the same manner (the subject in the 
“intermediate” category and those in the “high” category were the same).  
 
(1) FH scores’ comparison 
Table 12 presents selected characteristics of the subjects’ families according to different 
FH scores, when using both methods for expected risk calculation. Briefly, the average 
family size of subjects with no FH was 6.3 (sd=2.5), the average age of the FDR was 
59.7 (sd=9.1) and the average expected number of colorectal cancer cases in the family 
was 0.110 (sd=0.046) when using the method of internal data and 0.168 when using that 
of external data. The corresponding values for subjects with a positive FH of colorectal 
cancer were 6.7 (sd=2.9), 60.8 (sd=8.0) and 0.117 (sd=0.052) when using the method of 
internal data and 0.168 when using that of external data, respectively. Families with 2+ 
affected relatives were somewhat bigger and older than those with 1 affected relative.  
When we considered the two categories of the FH scores in which subjects with a 
positive FH were divided (i.e., the “intermediate” and the “high” categories), we found 
that, for most scores, families in the high categories were smaller, characterized by a 
lower average age and by a lower average number of expected colorectal cancer cases 
than those in the intermediate ones. These results were similar for both methods for the 
expected risk calculation in FDR. 
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In Table 13, the effect of using different methods of defining a positive FH on the odds 
of colorectal cancer is compared, as well as the goodness-of-fit and accuracy of these 
methods in predicting the development of such cancer. The analysis was performed for 
FH scores obtained with both the method of internal data and that of external data. 
Slack and Evans’s, Fain and Goldar’s, Lynch’s, and Reed’s scores gave the same 
information in terms of odds of colorectal cancer and goodness-of-fit, since they 
classified subjects in the same manner. Using the binary indicator (Yes vs No) resulted 
in an OR of 1.55 (95% CI, 1.02-2.37) for subjects with one or more FDR with 
colorectal cancer as compared to those with no affected relatives. Other FH scores 
divided subjects with at least one affected relative in an “intermediate” category and a 
“high” category. For most of them, in both scenarios (internal data and external data), 
the magnitude of the ORs increased with subsequent categories of the scores, although 
the differences in ORs were not so noticeable. However, statistical significance at 
=0.05 was not reached for most of the associations. On the contrary some FH scores 
found no increased risk (or a slight not significant risk) for the intermediate category, 
which included subjects with a positive FH but characterized by a relatively low value 
of the score, and a significant increased risk of colorectal cancer for the high category, 
in which subjects with a positive FH and characterized by a relatively high value of the 
score were included, as compared to no FH. In particular, in the internal data setting, 
FHS1 found a slightly 30% not significant increased risk of colorectal cancer for 
subjects in the intermediate category and a 80% significant increased risk for those in 
the high category. Similar results were observed for the Groenveld and Hitzeroth’s 
score in the external data setting. FHS2 fund ORs of 1.17 (95% CI, 0.62-2.12) for the 
intermediated category and 1.92 (95% CI, 1.09-3.38) for the high category as compared 
to no FH of colorectal cancer. Only the Chakraborty’s score in the internal data setting 
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and the Kee’s score and the Slack and Evans’s/Fain and Goldar’s/Lynch’s/Reed’s 
scores found an higher OR for the intermediate category than for the high one.  
With regard to the goodness-of-fit of the model, similar AUC were found for each FH 
score in both settings; no significant differences in AUC between each FH scores and 
the proportion emerged. 
 
 
2.4.2 Simulation 
Results for the simulations performed on various scenarios of π and RR, with expected 
risks of disease equal to 0.001, 0.01, 0.10 and 0.20 (Panel A) or 0.04, 0.08, 0.12, and 
0.16 (Panel B) according to the 4 age groups are reported in Table 14. Table 15 shows 
FH scores’ final ranking according to mean AUC. Based on mean AUC observation, 
Reed’s score appears the most efficient FH measure in all the 48 simulation settings, 
with mean AUC ranging from 0.551 to 0.944, while the binary indicator is the poorest 
all the scenarios, with mean AUC ranging from 0.534 to 0.739. 
FHS2 ranks second in 20 of the 48 simulations, third in 27/48 simulations, and fourth in 
one simulation only. However, this score, as it was mentioned before, is different from 
the others in its original formulation, since it calculates the expected risk of disease in 
relatives using information (i.e., disease status, the disease-free life experience, sex, and 
other factors) collected among these relatives, instead of using incidence rate of the 
disease in the area under investigation. In my simulation, in order to make FH scores 
comparable, I’ve used the same expected risk of disease in age strata for each score; 
thus results from the simulation do not take into account the differences between FHS2 
and the other FH scores in terms of the calculation of the expected risk of disease. 
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Schwartz’s score ranks third, with in general better performances with higher π when 
compared with other scores.  
Slacnck and Evans’ and Lynch scores have very similar performances in all the 
simulations, and rank fourth, followed by FHS1, Groenelved and Hitzeroth's score, 
proportion of affected relatives, and Fain and Goldar’s score. Besides the binary 
indicator, Chakraborty’s score (twelfth in the final ranking), Kee's score (eleventh in the 
final ranking) and the observed number of affected relatives (tenth in the final ranking) 
give the worst prediction of the level of risk of the families. 
Figure 5 and Figure 6 show how the performance of the different FH scores varies 
according to RR (Figure 5) and prevalence of high risk family in the population (Figure 
6), with expected risks of disease equal to 0.001, 0.01, 0.10 and 0.20 (Panel A) or 0.04, 
0.08, 0.12, 0.16 (Panel B) according to the 4 subsequent age groups. The following 
observation can be made from the results displayed: 
(a) except for the binary indicator, the performance of all the other FH scores decreases 
with the increase of the prevalence of families with high risk. This is particularly 
evident when the RR of FH is high (RR=3.0 or 4.0).  
(b) In general, the performance of all the FH score increases with the increase of the 
RR, regardless of the prevalence of families with high risk. However, the expected risks 
of diseases for the 4 age groups were set to 0.002, 0.01, 0.1, and 0.2 and π=0.0001, the 
mean AUC of most of the FH scores slightly decreases when RR increases from 3.0 to 
4.0 (the mean AUC from all the FH scores at RR=3.0 is 0.898, while the mean AUC at 
RR=3.0 is 0.896).  
(c) The RR for FH contributes to the FH score performance with a higher extent than 
the prevalence of families with high risk. 
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If we focus our attention on the proportion, which is the FH summary measure which 
performs better among the simplest ones (i.e., among those FH measures which do not 
require the estimate of the expected risk of disease for each relative; i.e., the binary 
indicator and the number of affected relatives), we found relatively small differences in 
mean AUC with the better scores (Table 16). In particular, the difference in mean AUC 
between the proportion and the Reed's score ranged from 0.003 (all the simulations with 
RR=1.2 when the expected risk of diseases were set to 0.04, 0.08, 0.12, and 0,16) to 
0.030 (simulation with π=0.4 and RR=4 when the expected risk of diseases were set to 
0.001, 0.01, 0.10 and 0.20), with a mean difference of 0.014. Differences between the 
proportion and the other scores are lower when the expected risks of disease were 0.04, 
0.08, 0.12, and 0,16 for the 4 subsequent age strata than when they were set to 0.001, 
0.01, 0.10 and 0.20. The gap in mean AUC between the proportion and the other scores 
increases with the increase of the RR.  
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2.5 Discussion 
The first preliminary approach in order to compare several different FH scores for 
measuring FR and recommend the measure that performs best, was to exploit real data 
collected from a well-conducted Italian case-control study on colorectal cancer. The 
values of 13 different FH scores were obtained for each study’s subjects on the basis of 
FH information on FDR. Two methods for the calculation of the expected risk of 
colorectal cancer in FDR were used: a method based on internal data only, as proposed 
by Silberberg et al [235], and a method using information on incidence rates of 
colorectal cancer in the area where enrolled subjects come from. Although ranges were 
different, the majority of the continuous FH scores ranked subjects very similarly. For 
most of the scores, for both methods for expected risk calculation, the magnitude of the 
ORs increased with subsequent categories of the scores, although significance at =0.05 
was not reached for most of the associations. On the other hand, FHS1 (when the 
internal data method for expected risk calculation was used), and the Groenveld and 
Hitzeroth’s score and FHS2 (when the external data method was used) seemed to be 
able to identify subjects at “intermediate” and at “high” risk of HCC among those with a 
positive FH. They have been shown to be able of identify subjects with positive FH of 
colorectal cancer who may have no increased risk of colorectal cancer, since coming 
from larger and older families, in which the expected risk of disease is higher. However, 
these FH scores did not provide a higher degree of predictive accuracy of colorectal 
cancer incidence than simply predicting that risk by designating FH as either positive or 
negative or using the proportion of affected relatives in a family. In fact, differences in 
the goodness-of-fit are small and not meaningful, and therefore seem to justify the use 
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of simplest FH scores, i.e., the binary indicator or the proportion of affected relatives, 
for the construction of which limited information on FDR is needed.  
Some considerations must be done. Colorectal cancer is a rare disease and the 
association with FH of the same disease is probably modest; in our dataset a small 
number of subjects reported therefore a positive FH of colorectal cancer, and only the 
10% of these (i.e., 6 cases and 4 controls) had 2 or more affected relatives. 
Consequently, the “intermediate” and the “high” categories of the FH scores included a 
small number of cases and controls, and this resulted in OR estimates characterized by 
wide CIs. We calculated FH scores on the basis of information about FDR only. 
Presumably, the possible effects of family structure and age on familial risk of 
colorectal cancer would be greater among extended families (i.e., considering also 
second-degree families) than among families defined on the basis of a first-degree 
relationship. Moreover, the number of colorectal cancer cases would be greater among 
extended families. The value of using FH scores to assess the impact of a positive FH 
on colorectal cancer risk should increase with a greater number of relatives and with the 
complexity of the pedigrees. Another point is about the calculation of the expected risks 
of disease in relatives that was performed in two ways: (a) directly from the data by a 
logistic model, without any validation versus external data, and (b) using age- and sex-
specific incidence rates of colorectal cancer from Varese and Friuli registers. A better 
estimation of the expected risks of colorectal cancer in relatives would be obtained if (a) 
information on other colorectal cancer risk factor were collected in relatives or (b) 
incidence rate of the disease in strata of other colorectal cancer risk factors were 
available. In light of these considerations, caution in interpreting or generalizing these 
results obtained by the Italian HI-WATE study is needed. Our consideration are only 
indicative for situation similar to our own, in which the outcome is a disease with 
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relatively low incidence rates and characterized by a positive modest association with 
FH of the same disease. 
Given the problems in comparing FH scores in a setting characterized by a rare outcome 
weakly associated with the FR, this issue has been also addressed through a more 
systematic approach. Different FH scores were compared using simulations of various 
settings in terms of prevalence of high risk families and RR of disease comparing high-
risk and low-risk individuals, in order to evaluate their accuracy of predicting the true 
FR. The advantage of this approach, as compared to the data-derived approach 
discussed before, is that scores may be evaluated on the basis of a known quantity, 
which is chosen at the beginning and that FH scores should estimate. It has been found 
that the performance of FH scores decreases with the increase of the prevalence of 
families with high risk, particularly with relatively high RRs. Moreover, in general, the 
performance increases with the increase of the RR of FH, regardless of the prevalence 
of families with high risk. More importantly, differences in predicting the true FR 
between FH scores were minor, although Reed’s score and FHS2 performed slightly 
better than most of the other scores, followed by the Schwartz’s score and the Slanck 
and Evans's score. The binary indicator was the worst predictor of the true FR, while the 
simple proportion of affected relatives, although ranking 8th in the final ranking, was 
characterized by small differences in mean AUC with the Reed’s score, and with the 
other scores with a better predictivity. These gaps in mean AUC between the proportion 
and the other scores increased with the increase of the RR and with the increase of the 
prevalence of high risk families, although to a lesser extent. Consequently, the use of 
the simple proportion seems justified, at least until stronger evidence is brought for the 
advantages of using a more complex score. 
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2.6 Tables and Figures of Chapter 2 
 
Table 7. Family history score. 
Score [year] (reference) Score formulation 
Binary indicator  Positive when 1jo  
Number of affected relatives  jo  
Proportion of affected relatives [1994]   [227] 
j
j
j
n
o
p   
Slack and Evans’s score [1996]  [228] 
j
j
e
o
 
Chakraborty’s score [1984]  [230]    )1(/
2
1 ijij
n
i ijij
eeeo
j
   
Fain and Goldar’s score [1986]  [231] 
)1( jj
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eo


 
Lynch’s score [1986]  [229] 
j
jj
e
eo 
 
Reed’s score [1986]  [236] 
j
jj
e
eo 
 
Schwartz’s score [1988]  [234]   ij
n
i ijij
eeo
j
/
1    
Groenelved and Hitzeroth’s score [1991]  
[232] 
    ijij
n
i ijij
j
eeeo
n
j
/1ln
1
1
   
Kee’s score [1991]  [233] 
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Silberberg’s scores [1999]  [235] 
 
ij
n
i ijij
j
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 78 
 
 
Table 8. Distribution of 474 cases of colorectal cancer and 561 controls according to 
center, sex, age, and other selected variables (Italian HI-WATE study). 
 
Cases Controls Total 
N % N % N % 
Centre 
240 (50.6) 247 (44.0) 487 (47.1) Pordenone/Udine 
Milano 234 (49.4) 314 (56.0) 548 (52.9) 
Age (yrs) 
116 (24.5) 149 (26.6) 265 (25.6) <60 
60-64 85 (17.9) 97 (17.3) 182 (17.6) 
65-69 110 (23.2) 126 (22.5) 236 (22.8) 
70-74 89 (18.8) 109 (19.4) 198 (19.1) 
≥75 74 (15.6) 80 (14.3) 154 (14.9) 
Sex 
310 (65.4) 366 (65.2) 676 (65.3) Male 
Female 164 (34.6) 195 (34.8) 359 (34.7) 
Education (years) 
161 (34.0) 225 (40.1) 386 (37.3) <7 
7-11 154 (32.5) 164 (29.2) 318 (30.7) 
≥12 159 (33.5) 172 (30.7) 331 (32.0) 
Body mass index (kg/m^2) 
a
 
19 (4.0) 26 (4.6) 45 (4.3) <20 
20-25 174 (36.7) 179 (31.9) 353 (34.1) 
25-30 188 (39.7) 249 (44.4) 437 (42.2) 
>30 92 (19.4) 103 (18.4) 195 (18.8) 
Physical activity 
a
 
91 (19.2) 132 (23.5) 223 (21.5) Hig 
Medium 119 (25.1) 115 (20.5) 234 (22.6) 
Low 263 (55.5) 307 (54.7) 570 (55.1) 
Alcohol (drinks/week) 
 a
 
150 (31.6) 225 (40.1) 375 (36.2) ≤7 
8-21 161 (34.0) 198 (35.3) 359 (34.7) 
>22 162 (34.2) 138 (24.6) 300 (29.0) 
Smoking habits 
a,b
 
191 (40.3) 235 (41.9) 426 (41.2) Never 
Ex 192 (40.5) 216 (38.5) 408 (39.4) 
Current,<15 cig/day 40 (8.4) 36 (6.4) 76 (7.3) 
Current, ≥15 cig/day 51 (10.8) 73 (13.0) 124 (12.0) 
Number of siblings 
53 (11.2) 56 (10.0) 109 (10.5) 0 
1 119 (25.1) 145 (25.8) 264 (25.5) 
2 90 (19.0) 109 (19.4) 199 (19.2) 
3 76 (16.0) 81 (14.4) 157 (15.2) 
≥4 136 (28.7) 170 (30.3) 306 (29.6) 
a 
The sum does not add up to the total because of some missing values. 
b 
Cigar equals 3 
cigarettes, 1 g of pipe tobacco equals 1 cigarette. 
 79 
 
Table 9. Results for the logistic regression model fitting the relative’s colorectal cancer 
status as a function of their age (in continuous) and sex. 
 
Analysis of Maximum Likelihood Estimates 
Parameter DF Estimate SE 
Wald  
Chi-square 
Intercept 1 -4.973 0.434 131.081 
sex 1 -0.258 0.192 1.811 
age 1 0.021 0.005 15.195 
 
 Odds Ratio Estimates 
Effect 
Point 
Estimate 
95% Wald 
Confidence Limits 
sex 0.773 0.531 1.125 
age 1.021 1.010 1.032 
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Figure 4. Distribution of expected risk of colorectal cancer in first-degree relatives 
using internal data only (in pink) and external data (i.e., cancer incidence rates from 
cancer registries; in blue). 
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Table 10. Summary measures describing the distribution of the different family history scores by the two methods for expected risk in FDR 
calculation. Only the distribution of the 11/13 continuous FH scores was presented. 
 
 
Internal data only  External data 
FH score mean median sd min max  mean median sd min max 
Proportion 0.02 0.00 0.07 0.00 0.50  0.02 0.00 0.07 0.00 0.50 
Slack and Evans 1.11 0.00 3.70 0.00 30.69  0.89 0.00 3.54 0.00 59.63 
Chakraborty 6.14 0.11 20.38 0.03 231.52  9.68E+13 0.16901 3.11E+15 0.0082 1.00E+17 
Fain and Goldar 0.02 -0.32 1.15 -0.63 7.08  -0.12 -0.40 1.07 -1.83 7.66 
Lynch 0.11 -1.00 3.70 -1.00 29.69  -0.11 -1.00 3.54 -1.00 58.63 
Reed 0.02 -0.31 1.09 -0.53 6.79  -0.10 -0.37 0.99 -0.88 7.59 
Schwartz -0.01 -0.71 2.62 -1.97 24.74  306125.71 -0.68 9838974.58 -2.79 316227765.51 
Groenelved and Hitzeroth 0.01 -0.07 0.26 -0.10 1.98  -0.01 -0.07 0.35 -0.22 7.77 
Kee 0.54 -3.08 13.75 -6.09 164.51  0.20 -2.49 18.48 -11.10 452.73 
FHS1 0.01 -0.13 0.49 -0.17 3.76  61225.15 -0.13 1967794.92 -0.33 63245553.10 
FHS2 0.00 -0.02 0.07 -0.03 0.48  -0.01 -0.02 0.07 -0.11 0.49 
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Table 11. Joint distribution of the Italian HI-WATE case-control study participants according 
to the family history (FH) scores categories and the observed number of first-degree relatives 
(FDR) with colorectal cancer, for both methods for expected risk calculation. 
 INTERNAL DATA  EXTERNAL DATA 
 N. of affected FDR  N. of affected FDR 
FH score 0 1 2+  0 1 2+ 
Proportion        
Low 930 0 0  930 0 0 
Intermediate 0 54 0  0 54 0 
High 0 39 10  0 39 10 
Slack and Evans, Fain and Goldar, Lynch, Reed     
Low 930 0 0  930 0 0 
Intermediate 0 48 0  0 52 0 
High 0 45 10  0 41 10 
Chakraborty
a 
       
Low 930 0 0  930 0 0 
Intermediate 0 51 0  0 47 1 
High 0 42 10  0 46 9 
Schwartz
a 
       
Low 930 0 0  930 0 0 
Intermediate 0 47 0  0 47 1 
High 0 46 10  0 46 9 
Groenelved and Hitzeroth
b 
       
Low 930 0 0  930 0 0 
Intermediate 0 48 0  0 44 1 
High 0 45 10  0 49 9 
Kee        
Low 930 0 0  930 0 0 
Intermediate 0 47 2  0 52 1 
High 0 46 8  0 41 9 
FHS1
b 
       
Low 930 0 0  930 0 0 
Intermediate 0 46 0  0 44 1 
High 0 47 10  0 49 9 
FHS2        
Low 930 0 0  930 0 0 
Intermediate 0 48 0  0 43 1 
High 0 45 10  0 50 9 
a
 The classification of the study subjects by the Chakraborty’s score is different from that by 
the Schwartz’s score. 
b
 The classification of the study subjects by the Groenelved and Hitzeroth’s score is different 
from that by the FHS1.
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Table 12. Characteristics of the study subjects’ families according to different family history scores.  
 
INTERNAL DATA 
 
 
N. of 
families 
Average 
family size SD 
Average age 
of the family SD 
Average 
expected risk of 
disease in a 
family SD 
No family history  930 6.3 2.5 59.7 9.1 0.110 0.046 
Binary indicator        
Yes 103 6.7 2.9 60.8 8.0 0.117 0.052 
N. of affected 
relatives 
       
1 93 6.6 2.8 60.6 8.2 0.116 0.053 
2+ 10 7.3 3.1 63.3 5.9 0.128 0.047 
Proportion        
Intermediate 54 8.4 2.4 59.9 6.7 0.147 0.048 
High 49 4.8 2.1 61.8 9.1 0.084 0.033 
Slanck and Evan, Fain 
and Goldar, Lynch, Reed 
     
Intermediate 48 8.6 2.4 61.1 5.8 0.154 0.046 
High 55 4.9 2.0 60.6 9.6 0.085 0.031 
Chakraborty        
Intermediate 51 6.2 2.8 61.6 8.9 0.113 0.056 
High 52 7.1 2.8 60.0 7.0 0.121 0.048 
Swartz        
Intermediate 47 7.1 3.2 61.4 8.3 0.129 0.061 
High 56 6.3 2.5 60.3 7.7 0.107 0.042 
Groenelved and 
Hitzeroth 
       
Intermediate 48 8.6 2.4 59.9 6.9 0.152 0.048 
High 55 4.9 2.0 61.6 8.8 0.086 0.032 
Kee        
Intermediate 49 8.8 2.5 61.2 5.5 0.157 0.046 
High 54 4.7 1.3 60.5 9.7 0.081 0.020 
FHS1        
Intermediate 46 8.7 2.5 59.4 7.0 0.152 0.050 
High 57 5.1 2.0 62.0 8.6 0.089 0.033 
FHS2        
Intermediate 48 8.6 2.4 60.9 6.4 0.154 0.047 
High 55 4.9 2.0 60.8 9.2 0.085 0.031 
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EXTERNAL DATA 
 
 
N. of 
families 
Average 
family size SD 
Average age 
of the family SD 
Average 
expected risk of 
disease in a 
family SD 
No family history  930 6.3 2.5 59.7 9.1 0.168 0.101 
Binary indicator        
Yes 103 6.7 2.9 60.8 8.0 0.171 0.099 
N. of affected 
relatives 
       
1 93 6.6 2.8 60.6 8.2 0.172 0.103 
2+ 10 7.3 3.1 63.3 5.9 0.165 0.050 
Proportion        
Intermediate 54 8.4 2.4 59.9 6.7 0.218 0.107 
High 49 4.8 2.1 61.8 9.1 0.120 0.054 
Slanck and Evan, Fain and 
Goldar, Lynch, Reed 
     
Intermediate 52 7.9 2.9 62.2 7.4 0.232 0.100 
High 51 5.4 2.2 59.4 8.4 0.109 0.044 
Chakraborty        
Intermediate 48 6.3 3.0 61.8 8.1 0.173 0.112 
High 55 7.0 2.7 60.0 7.9 0.170 0.086 
Swartz        
Intermediate 48 6.6 3.0 61.6 7.8 0.182 0.114 
High 55 6.7 2.7 60.1 8.1 0.162 0.083 
Groenelved and 
Hitzeroth 
       
Intermediate 45 8.2 3.0 60.1 6.6 0.215 0.118 
High 58 5.4 2.0 61.4 8.9 0.137 0.063 
Kee        
Intermediate 53 7.8 2.9 62.5 7.5 0.232 0.099 
High 50 5.5 2.3 59.1 8.2 0.107 0.041 
FHS1        
Intermediate 45 8.0 3.1 60.1 6.6 0.212 0.120 
High 58 5.6 2.2 61.3 9.0 0.140 0.063 
FHS2        
Intermediate 44 8.8 2.8 61.4 5.8 0.229 0.116 
High 59 5.0 1.6 60.4 9.3 0.129 0.053 
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Table 13. Summary of estimates from logistic regression analysis by different family history 
(FH) measures, using both methods for the expected risk calculation. 
 INTERNAL DATA EXTERNAL DATA 
FH score OR
a
  
(95% CI) 
AUC 
(p
b
) 
OR
a
  
(95% CI) 
AUC 
(p
b
) 
     
Binary indicator     
Yes 1.55 (1.02-2.37) 0.629 
(0.771) 
1.55 (1.02-2.37) 0.629 
(0.711) 
Number of affected relatives     
1 1.54 (0.99-2.41) 0.629 1.54 (0.99-2.41) 0.629 
2+ 1.63 (0.45-6.00) (0.980) 1.63 (0.45-6.00) (0.980) 
Proportion     
Intermediate 1.45 (0.81-2.59) 0.629 1.45 (0.81-2.59) 0.629 
High 1.67 (0.91-3.07) - 1.67 (0.91-3.07) - 
Slack and Evans, Fain and 
Goldar, Lynch, and Reed 
    
Intermediate 1.38 (0.75-2.55) 0.628 1.58 (0.88-2.85) 0.629 
High 1.72 (0.96-3.06) (0.661) 1.52 (0.84-2.74) (0.821) 
Chakraborty     
Intermediate 1.68 (0.93-3.02) 0.630 1.47 (0.81-2.68) 0.628 
High 1.44 (0.80-2.57) (0.294) 1.63 (0.92-2.88) (0.723) 
Schwartz     
Intermediate 1.44 (0.79-2.63) 0.628 1.52 (0.84-2.76) 0.629 
High 1.66 (0.94-2.93) (0.748) 1.58 (0.89-2.80) (0.958) 
Groenelved and Hitzeroth     
Intermediate 1.41 (0.77-2.60) 0.629 1.33 (0.72-2.48) 0.628 
High 1.69 (0.95-3.00) (0.733) 1.76 (1.00-3.08) (0.463) 
Kee     
Intermediate 1.44 (0.78-2.64) 0.629 1.64 (0.92-2.95) 0.630 
High 1.67 (0.93-2.98) (0.867) 1.46 (0.81-2.65) (0.517) 
FHS-1     
Intermediate 1.31 (0.70-2.43) 0.628 1.35 (0.73-2.51) 0.627 
High 1.79 (1.01-3.16) (0.781) 1.74 (0.99-3.05) (0.304) 
FHS-2     
Intermediate 1.39 (0.76-2.57) 0.629 1.17 (0.62-2.21) 0.629 
High 1.71 (0.96-3.04) (0.724) 1.92 (1.09-3.38) (0.837) 
     
a
 Estimated from unconditional multiple logistic regression model adjusted for age, sex, center 
and education, body mass index, physical activity, tobacco smoking, alcohol drinking, and 
number of siblings. Reference category: no family history of colorectal cancer.  
b
 p value for nonparametric tests comparing AUCs for models including continuous FH scores 
with AUC for model including the proportion indicator. 
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Table 14. AUC for 200 simulations with expected risk of diseases equal to 0.001, 0.01, 0.10 
and 0.20 (Panel A) or 0.04, 0.08, 0.12, 0.16 (Panel B) for the four age strata (i.e., <45, 45-55, 
56-65, >56), respectively, according to different prevalences of families at high risk in the 
population (i.e., 1‱, 1 ‰, 5%, 10%, 20% or 40%) and to different relative risks (RR) for 
high vs low risk families (i.e., 1.2, 2.0, 3.0 or 4.0). The four highest values of mean AUC 
were underline in orange; the four lowest values in blue. 
 
PANEL A 
 
 
Prevalence=0.0001 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.534 0.008 0.625 0.009 0.604 0.010 0.705 0.012 
Number of affected 0.545 0.006 0.690 0.008 0.895 0.009 0.890 0.008 
FHS1 0.549 0.006 0.707 0.008 0.934 0.007 0.914 0.007 
FHS2 0.550 0.006 0.716 0.008 0.950 0.006 0.931 0.006 
Proportion 0.547 0.007 0.702 0.008 0.936 0.006 0.913 0.007 
Slanck and Evans 0.547 0.006 0.706 0.008 0.950 0.006 0.927 0.007 
Groenelved and Hitzeroth 0.548 0.006 0.706 0.008 0.922 0.007 0.915 0.007 
Fain and Goldar 0.546 0.011 0.697 0.011 0.869 0.019 0.907 0.009 
Kee 0.540 0.016 0.690 0.009 0.938 0.007 0.910 0.008 
Lynch 0.547 0.006 0.706 0.008 0.950 0.006 0.927 0.007 
Reed 0.552 0.005 0.721 0.008 0.953 0.005 0.937 0.006 
Chakraborty 0.537 0.008 0.659 0.009 0.843 0.011 0.845 0.010 
Schwartz 0.551 0.005 0.713 0.008 0.930 0.007 0.914 0.007 
 
  Prevalence=0.001 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.534 0.008 0.625 0.009 0.680 0.012 0.705 0.011 
Number of affected 0.545 0.006 0.690 0.008 0.814 0.010 0.889 0.008 
FHS1 0.549 0.006 0.707 0.008 0.838 0.009 0.914 0.007 
FHS2 0.550 0.006 0.715 0.008 0.853 0.009 0.930 0.006 
Proportion 0.547 0.007 0.702 0.008 0.834 0.009 0.913 0.007 
Slanck and Evans 0.547 0.006 0.706 0.008 0.845 0.009 0.927 0.007 
Groenelved and Hitzeroth 0.548 0.006 0.706 0.008 0.838 0.009 0.915 0.007 
Fain and Goldar 0.546 0.011 0.697 0.011 0.828 0.012 0.907 0.009 
Kee 0.540 0.016 0.690 0.009 0.825 0.009 0.909 0.008 
Lynch 0.547 0.006 0.706 0.008 0.845 0.009 0.927 0.007 
Reed 0.552 0.005 0.721 0.008 0.859 0.008 0.936 0.006 
Chakraborty 0.537 0.008 0.659 0.009 0.770 0.010 0.845 0.010 
Schwartz 0.551 0.005 0.713 0.008 0.842 0.009 0.914 0.007 
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  Prevalence=0.05 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.534 0.007 0.625 0.009 0.687 0.012 0.719 0.011 
Number of affected 0.545 0.006 0.685 0.008 0.802 0.010 0.872 0.008 
FHS1 0.548 0.006 0.701 0.008 0.825 0.009 0.897 0.008 
FHS2 0.550 0.006 0.709 0.008 0.838 0.009 0.911 0.007 
Proportion 0.547 0.007 0.696 0.008 0.820 0.009 0.893 0.008 
Slanck and Evans 0.547 0.006 0.699 0.008 0.828 0.009 0.904 0.007 
Groenelved and Hitzeroth 0.548 0.006 0.700 0.008 0.824 0.009 0.897 0.007 
Fain and Goldar 0.545 0.011 0.691 0.011 0.815 0.012 0.889 0.009 
Kee 0.540 0.016 0.683 0.009 0.808 0.010 0.885 0.008 
Lynch 0.547 0.006 0.699 0.008 0.828 0.009 0.904 0.007 
Reed 0.552 0.005 0.715 0.007 0.845 0.008 0.917 0.006 
Chakraborty 0.537 0.008 0.655 0.009 0.759 0.010 0.828 0.010 
Schwartz 0.551 0.005 0.708 0.007 0.831 0.009 0.900 0.007 
 
  Prevalence=0.1 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.534 0.007 0.626 0.009 0.690 0.010 0.729 0.012 
Number of affected 0.545 0.006 0.681 0.008 0.789 0.008 0.856 0.009 
FHS1 0.548 0.006 0.697 0.008 0.812 0.008 0.880 0.008 
FHS2 0.550 0.006 0.704 0.008 0.823 0.008 0.893 0.007 
Proportion 0.546 0.006 0.690 0.008 0.805 0.008 0.874 0.008 
Slanck and Evans 0.547 0.006 0.694 0.008 0.812 0.008 0.882 0.008 
Groenelved and Hitzeroth 0.548 0.006 0.696 0.008 0.811 0.008 0.880 0.008 
Fain and Goldar 0.545 0.011 0.686 0.011 0.801 0.010 0.872 0.010 
Kee 0.540 0.016 0.677 0.009 0.791 0.009 0.862 0.009 
Lynch 0.547 0.006 0.694 0.008 0.812 0.008 0.882 0.008 
Reed 0.552 0.005 0.709 0.007 0.830 0.008 0.899 0.007 
Chakraborty 0.536 0.008 0.651 0.009 0.748 0.009 0.812 0.010 
Schwartz 0.550 0.005 0.703 0.007 0.819 0.008 0.886 0.008 
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  Prevalence=0.2 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.534 0.007 0.626 0.009 0.694 0.010 0.737 0.011 
Number of affected 0.544 0.006 0.673 0.007 0.769 0.008 0.827 0.008 
FHS1 0.548 0.006 0.688 0.008 0.790 0.009 0.850 0.008 
FHS2 0.549 0.006 0.694 0.008 0.800 0.009 0.861 0.008 
Proportion 0.546 0.006 0.681 0.007 0.781 0.008 0.841 0.007 
Slanck and Evans 0.546 0.006 0.683 0.008 0.786 0.008 0.846 0.008 
Groenelved and Hitzeroth 0.547 0.006 0.686 0.008 0.789 0.009 0.849 0.008 
Fain and Goldar 0.545 0.011 0.678 0.011 0.779 0.011 0.840 0.010 
Kee 0.539 0.015 0.667 0.009 0.763 0.009 0.822 0.009 
Lynch 0.546 0.006 0.683 0.008 0.786 0.008 0.846 0.008 
Reed 0.551 0.005 0.700 0.007 0.807 0.008 0.868 0.007 
Chakraborty 0.536 0.008 0.644 0.009 0.729 0.010 0.784 0.009 
Schwartz 0.550 0.005 0.695 0.007 0.799 0.008 0.859 0.007 
 
  Prevalence=0.4 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.534 0.007 0.624 0.008 0.691 0.010 0.733 0.009 
Number of affected 0.543 0.006 0.658 0.007 0.737 0.008 0.782 0.008 
FHS1 0.547 0.006 0.672 0.008 0.757 0.009 0.804 0.009 
FHS2 0.548 0.006 0.677 0.008 0.763 0.009 0.811 0.009 
Proportion 0.545 0.006 0.664 0.007 0.745 0.008 0.790 0.008 
Slanck and Evans 0.545 0.006 0.666 0.007 0.747 0.008 0.792 0.008 
Groenelved and Hitzeroth 0.546 0.006 0.671 0.008 0.755 0.009 0.803 0.009 
Fain and Goldar 0.544 0.011 0.661 0.011 0.743 0.011 0.789 0.011 
Kee 0.537 0.017 0.649 0.009 0.722 0.009 0.764 0.009 
Lynch 0.545 0.006 0.666 0.007 0.747 0.008 0.792 0.008 
Reed 0.550 0.005 0.683 0.007 0.771 0.008 0.820 0.008 
Chakraborty 0.535 0.008 0.632 0.009 0.700 0.010 0.741 0.009 
Schwartz 0.549 0.005 0.679 0.007 0.766 0.008 0.814 0.008 
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PANEL B 
 
 
  Prevalence=0.0001 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.535 0.007 0.621 0.010 0.667 0.012 0.685 0.013 
Number of affected 0.550 0.006 0.708 0.009 0.834 0.009 0.909 0.008 
FHS1 0.553 0.006 0.723 0.009 0.859 0.009 0.935 0.006 
FHS2 0.554 0.006 0.728 0.009 0.865 0.008 0.941 0.005 
Proportion 0.553 0.006 0.723 0.009 0.860 0.008 0.937 0.006 
Slanck and Evans 0.553 0.006 0.725 0.009 0.863 0.008 0.940 0.006 
Groenelved and Hitzeroth 0.553 0.006 0.723 0.009 0.859 0.009 0.935 0.006 
Fain and Goldar 0.550 0.014 0.705 0.014 0.832 0.013 0.908 0.010 
Kee 0.550 0.007 0.714 0.010 0.851 0.009 0.930 0.006 
Lynch 0.553 0.006 0.725 0.009 0.863 0.008 0.940 0.006 
Reed 0.556 0.005 0.733 0.009 0.870 0.008 0.944 0.005 
Chakraborty 0.545 0.008 0.688 0.010 0.809 0.010 0.885 0.009 
Schwartz 0.556 0.005 0.729 0.009 0.861 0.008 0.933 0.006 
 
 
  Prevalence=0.001 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.535 0.007 0.621 0.010 0.667 0.012 0.685 0.013 
Number of affected 0.550 0.006 0.708 0.009 0.834 0.009 0.909 0.008 
FHS1 0.553 0.006 0.723 0.009 0.858 0.009 0.935 0.006 
FHS2 0.554 0.006 0.727 0.009 0.865 0.008 0.941 0.006 
Proportion 0.553 0.006 0.723 0.009 0.860 0.008 0.937 0.006 
Slanck and Evans 0.553 0.006 0.725 0.009 0.863 0.008 0.940 0.006 
Groenelved and Hitzeroth 0.553 0.006 0.723 0.009 0.858 0.009 0.935 0.006 
Fain and Goldar 0.550 0.014 0.705 0.014 0.832 0.013 0.908 0.010 
Kee 0.550 0.008 0.714 0.010 0.850 0.009 0.930 0.007 
Lynch 0.553 0.006 0.725 0.009 0.863 0.008 0.940 0.006 
Reed 0.556 0.005 0.733 0.009 0.870 0.008 0.944 0.006 
Chakraborty 0.545 0.008 0.688 0.010 0.809 0.010 0.885 0.009 
Schwartz 0.556 0.005 0.729 0.009 0.861 0.008 0.933 0.006 
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  Prevalence=0.05 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.535 0.007 0.623 0.010 0.676 0.012 0.703 0.013 
Number of affected 0.550 0.006 0.703 0.009 0.822 0.009 0.893 0.008 
FHS1 0.553 0.006 0.717 0.009 0.844 0.009 0.917 0.007 
FHS2 0.554 0.006 0.721 0.009 0.850 0.009 0.922 0.006 
Proportion 0.553 0.006 0.717 0.009 0.845 0.009 0.917 0.006 
Slanck and Evans 0.553 0.006 0.718 0.009 0.847 0.009 0.920 0.007 
Groenelved and Hitzeroth 0.553 0.006 0.717 0.009 0.844 0.009 0.916 0.007 
Fain and Goldar 0.550 0.014 0.700 0.014 0.820 0.013 0.892 0.011 
Kee 0.549 0.007 0.707 0.010 0.835 0.009 0.909 0.007 
Lynch 0.553 0.006 0.718 0.009 0.847 0.009 0.920 0.007 
Reed 0.556 0.005 0.728 0.009 0.856 0.008 0.927 0.006 
Chakraborty 0.545 0.008 0.683 0.010 0.797 0.010 0.868 0.010 
Schwartz 0.555 0.005 0.723 0.009 0.849 0.009 0.918 0.007 
 
 
 
  Prevalence=0.1 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.535 0.007 0.625 0.010 0.683 0.012 0.717 0.013 
Number of affected 0.550 0.006 0.698 0.009 0.811 0.009 0.877 0.008 
FHS1 0.553 0.006 0.712 0.009 0.831 0.009 0.898 0.008 
FHS2 0.554 0.006 0.716 0.009 0.837 0.009 0.904 0.007 
Proportion 0.553 0.006 0.711 0.008 0.831 0.009 0.899 0.007 
Slanck and Evans 0.553 0.006 0.712 0.009 0.833 0.009 0.901 0.008 
Groenelved and Hitzeroth 0.553 0.006 0.711 0.009 0.831 0.009 0.898 0.008 
Fain and Goldar 0.549 0.015 0.695 0.014 0.808 0.013 0.875 0.011 
Kee 0.549 0.008 0.701 0.009 0.820 0.010 0.889 0.009 
Lynch 0.553 0.006 0.712 0.009 0.833 0.009 0.901 0.008 
Reed 0.556 0.005 0.722 0.008 0.844 0.009 0.910 0.007 
Chakraborty 0.544 0.008 0.679 0.010 0.785 0.010 0.851 0.010 
Schwartz 0.555 0.005 0.718 0.008 0.837 0.009 0.903 0.007 
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  Prevalence=0.2 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.535 0.007 0.626 0.010 0.691 0.012 0.732 0.012 
Number of affected 0.549 0.006 0.689 0.009 0.790 0.009 0.849 0.008 
FHS1 0.552 0.006 0.701 0.009 0.808 0.009 0.868 0.009 
FHS2 0.553 0.006 0.705 0.009 0.813 0.009 0.873 0.008 
Proportion 0.552 0.006 0.701 0.008 0.807 0.009 0.867 0.008 
Slanck and Evans 0.552 0.006 0.702 0.009 0.808 0.009 0.868 0.008 
Groenelved and Hitzeroth 0.552 0.007 0.701 0.009 0.808 0.009 0.868 0.009 
Fain and Goldar 0.549 0.015 0.686 0.014 0.787 0.014 0.847 0.012 
Kee 0.548 0.008 0.690 0.010 0.794 0.010 0.853 0.009 
Lynch 0.552 0.006 0.702 0.009 0.808 0.009 0.868 0.008 
Reed 0.555 0.005 0.712 0.008 0.821 0.009 0.881 0.008 
Chakraborty 0.544 0.008 0.670 0.010 0.765 0.011 0.823 0.010 
Schwartz 0.554 0.005 0.709 0.008 0.817 0.009 0.877 0.008 
 
 
  Prevalence=0.4 
  RR=1.2 RR=2.0 RR=3.0 RR=4.0 
FH SCORE mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
mean 
(AUC) 
std 
(AUC) 
Binary indicator 0.535 0.008 0.627 0.010 0.695 0.010 0.739 0.011 
Number of affected 0.548 0.006 0.674 0.008 0.758 0.009 0.806 0.008 
FHS1 0.551 0.007 0.684 0.009 0.771 0.010 0.820 0.009 
FHS2 0.552 0.006 0.687 0.009 0.775 0.009 0.824 0.009 
Proportion 0.551 0.006 0.683 0.008 0.769 0.009 0.817 0.009 
Slanck and Evans 0.551 0.006 0.683 0.008 0.770 0.009 0.817 0.009 
Groenelved and Hitzeroth 0.551 0.007 0.684 0.009 0.771 0.009 0.820 0.009 
Fain and Goldar 0.548 0.015 0.669 0.015 0.752 0.014 0.799 0.013 
Kee 0.547 0.008 0.671 0.010 0.752 0.010 0.798 0.010 
Lynch 0.551 0.006 0.683 0.008 0.770 0.009 0.817 0.009 
Reed 0.554 0.005 0.695 0.008 0.786 0.009 0.836 0.009 
Chakraborty 0.543 0.008 0.656 0.009 0.733 0.010 0.778 0.010 
Schwartz 0.553 0.005 0.692 0.008 0.783 0.009 0.833 0.009 
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Table 14.  Family history scores' final ranking according to mean AUC. 
 
 
 
 
Final Ranking 
1 - Reed's score 
2 - FHS2 
3 - Schwartz's score 
4 - Slanck and Evans's score 
5 - Lynch's score 
6 - FHS1 
7 - Groenelved and Hitzeroth's score 
8 - Proportion 
9 - Fain and Goldar's score 
10 - Number of affected relatives 
11 - Kee's score 
12 - Chakraborty's score 
13 - Binary indicator 
 93 
 
Figure 5. Mean AUC for different FH scores in relation with prevalence of family at high risk, by different relative risk of FH, with expected risks of 
disease equal to 0.001, 0.01, 0.10 and 0.20 (Panel A) or 0.04, 0.08, 0.12, 0.16 (Panel B) according to subsequent age groups. 
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PANEL B 
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Figure 6. Mean AUC for different FH scores in relation with RR, by different prevalences of family at high risk, with expected risks of disease equal 
to 0.001, 0.01, 0.10 and 0.20 (Panel A) or 0.04, 0.08, 0.12, 0.16 (Panel B) according to subsequent age groups. 
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PANEL B 
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Table 16.  Differences in mean AUC between the proportion of affected relatives and those FH scores with a better predictivity. 
 
 
SIMULATION 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Reed 
0.005 0.019 0.016 0.023 0.005 0.019 0.025 0.023 0.005 0.019 0.025 0.024 0.005 0.019 0.025 0.025 0.005 0.019 0.025 0.027 0.005 0.018 0.026 0.030 
0.003 0.01 0.01 0.007 0.003 0.01 0.01 0.007 0.003 0.011 0.011 0.01 0.003 0.011 0.013 0.011 0.003 0.011 0.014 0.014 0.003 0.012 0.017 0.019 
FHS2 
0.003 0.014 0.013 0.017 0.003 0.014 0.019 0.018 0.003 0.014 0.019 0.018 0.003 0.013 0.018 0.019 0.003 0.013 0.018 0.020 0.003 0.013 0.018 0.021 
0.001 0.005 0.005 0.004 0.001 0.004 0.005 0.004 0.001 0.004 0.005 0.005 0.001 0.005 0.006 0.005 0.001 0.004 0.006 0.006 0.001 0.004 0.006 0.007 
Schwartz 
0.004 0.011 -0.007 0.001 0.004 0.012 0.008 0.001 0.004 0.012 0.011 0.007 0.004 0.013 0.014 0.012 0.004 0.014 0.018 0.018 0.004 0.015 0.021 0.024 
0.003 0.006 0.001 -0.004 0.003 0.006 0.001 -0.004 0.002 0.006 0.004 0.001 0.002 0.007 0.006 0.004 0.002 0.008 0.01 0.01 0.002 0.009 0.014 0.016 
SE 
0.000 0.004 0.014 0.014 0.000 0.004 0.010 0.014 0.000 0.004 0.008 0.011 0.000 0.003 0.007 0.008 0.000 0.002 0.004 0.005 0.000 0.001 0.002 0.002 
0 0.002 0.003 0.003 0 0.002 0.003 0.003 0 0.001 0.002 0.003 0 0.001 0.002 0.002 0 0.001 0.001 0.001 0 0 0.001 0 
Lynch 
0.000 0.004 0.014 0.014 0.000 0.004 0.010 0.014 0.000 0.004 0.008 0.011 0.000 0.003 0.007 0.008 0.000 0.002 0.004 0.005 0.000 0.001 0.002 0.002 
0 0.002 0.003 0.003 0 0.002 0.003 0.003 0 0.001 0.002 0.003 0 0.001 0.002 0.002 0 0.001 0.001 0.001 0 0 0.001 0 
FHS1 
0.002 0.005 -0.003 0.001 0.002 0.005 0.004 0.001 0.002 0.006 0.005 0.004 0.002 0.006 0.007 0.006 0.002 0.007 0.009 0.010 0.002 0.008 0.012 0.014 
0 0 -0.001 -0.002 0 0 -0.002 -0.002 0 0 -0.001 0 0 0.001 0 -0.001 0 0 0.001 0.001 0 0.001 0.002 0.003 
GH 
0.001 0.004 -0.014 0.002 0.001 0.004 0.003 0.002 0.001 0.005 0.005 0.004 0.001 0.005 0.006 0.005 0.002 0.006 0.008 0.009 0.002 0.007 0.010 0.013 
0 0 -0.001 -0.002 0 0 -0.002 -0.002 0 0 -0.001 -0.001 0 0 0 -0.001 0 0 0.001 0.001 0 0.001 0.002 0.003 
 
Abbreviations: FH, FH; GH, Groenelved and Hitzeroth; SE, Slanck and Evans. 
Legend of Table 16: For each family history score, in the first row are displayed results for 24 different settings (according to different RRs and π) with 
expected risks of disease equal to 0.001, 0.01, 0.1 an 0.4 for the 4 subsequent age groups; in the second row are displayed results for 24 different settings 
(according to different RRs and π) with expected risks of disease equal to 0.04, 0.08, 0.12, 0.16. Simulation 1: π=0.0001 - RR=1.2; Simulation 2: π=0.0001 - 
RR=2.0; Simulation 3: π=0.0001 - RR=3.0; Simulation 4: π=0.0001 - RR=4.0; Simulation 5: π=0.001 - RR=1.2; Simulation 6: π=0.001 - RR=2.0; Simulation 
7: π=0.001 - RR=3.0; Simulation 8: π=0.001 - RR=4.0; Simulation 9: π=0.05 - RR=1.2; Simulation 10: π=0.05 - RR=2.0; Simulation 11: π=0.05 - RR=3.0; 
Simulation 12: π=0.05 - RR=4.0; Simulation 13: π=0.1 - RR=1.2; Simulation 14: π=0.1 - RR=2.0; Simulation 15: π=0. 1 - RR=3.0; Simulation 16: π=0.1 - 
RR=4.0; Simulation 17: π=0.2 - RR=1.2; Simulation 18: π=0.2 - RR=2.0; Simulation 19: π=0.2 - RR=3.0; Simulation 20: π=0.2 - RR=4.0; Simulation 21: 
π=0.4 - RR=1.2; Simulation 22: π=0.4 - RR=2.0; Simulation 23: π=0.4 - RR=3.0; Simulation 24: π=0.4 - RR=4.0. 
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